

## Community pharmacy: promoting health and wellbeing

**Evidence reviews for signposting and referral to  
other services and support**

*NICE guideline <number>*

*Evidence reviews*

*[January, 2018]*

*Draft for Consultation*

*These evidence reviews were developed  
by the Public Health internal guidelines  
team*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© National Institute for Health and Care Excellence, 2018. All rights reserved.

ISBN:

## Contents

<b>Signposting and referral to other services and support .....</b>	<b>6</b>
Review question .....	6
Introduction .....	6
PICO table.....	6
Effectiveness evidence.....	7
Summary of effectiveness studies included in the evidence review .....	8
Synthesis and quality assessment of effectiveness evidence included in the review .....	8
Acceptability evidence .....	10
Summary of acceptability studies included in the evidence review .....	11
Quality assessment of acceptability studies included in the evidence review.....	11
Economic evidence .....	12
Economic model.....	12
Evidence statements .....	12
Recommendations .....	13
Evidence discussion.....	15
<b>Appendices.....</b>	<b>19</b>
Appendix A – Review protocols .....	19
Review question 4a - Effectiveness of signposting and referral .....	19
Review question 4b - Acceptability of signposting and referral .....	21
Review question 4c - Cost effectiveness of signposting or referral .....	23
Common elements across reviews 1 to 4 .....	25
Appendix B – Literature search strategies .....	34
Appendix C – Effectiveness and acceptability included evidence .....	34
Appendix Di – Effectiveness evidence tables.....	35
Appendix Dii – Acceptability evidence tables .....	44
Appendix E – Forest plots.....	46
Appendix F – GRADE tables .....	47
GRADE profile 1: Uptake of services.....	47
Appendix G – Economic evidence study selection.....	48
Appendix H – Economic evidence tables.....	48
Appendix I – Health economic evidence profiles.....	48
Appendix J – Health economic analysis.....	48
Appendix K – Excluded studies .....	48
Appendix L – Research recommendations .....	48
Appendix M – Expert testimony .....	50
Appendix N – PRISMA diagram.....	51



# 1 Signposting and referral to other services 2 and support

## 3 Review question

4 **Review question 4a:** What is the most effective way for community pharmacies to refer or  
5 signpost people to other services or support?

6 **Review question 4b:** Is offering signposting and referral acceptable to users of community  
7 pharmacy services?

8 **Review question 4c:** What is the most cost effective way for community pharmacies to refer  
9 or signpost people to other services or support?

## 10 Introduction

11 Community pharmacies are well positioned to promote health and wellbeing to their local  
12 community as 90% of people overall, and over 99% of people in the most deprived  
13 communities, live within a 20-minute walk of a community pharmacy ([The positive pharmacy  
14 care law: an area-level analysis of the relationship between community pharmacy  
15 distribution, urbanity and social deprivation in England](#) Todd et al. 2014).

16 As well as promoting healthy lifestyles, community pharmacy contractors are required to  
17 signpost members of the community to appropriate services. This involves providing  
18 information on other health and social care providers or support organisations to people who  
19 need support, advice or treatment that cannot be provided by the pharmacy.

20 The aim of this review was to determine the most effective and cost-effective way for  
21 community pharmacy staff to refer or signpost people from community pharmacy to other  
22 services or support, and whether offering signposting and referral is acceptable to users of  
23 community pharmacy services.

24 This review also aims to explore whether the effectiveness and cost-effectiveness of  
25 signposting and referral varies by the characteristics of the intervention, the person providing  
26 the signposting and referral, or the person being signposted or referred. It will also explore  
27 how signposting and referral could be made more acceptable to users of community  
28 pharmacy services.

29 The review focused on identifying studies that fulfilled the criteria specified in Table 1. For full  
30 details of the review protocol, see Appendix A.

## 31 PICO table

32 **Table 1. PICO table for review questions 4a, 4b and 4c on signposting and referral**

PICO Element	Details
Population	Anyone who may use community pharmacy services
Intervention	<ul style="list-style-type: none"><li>• Any type of referral made by community pharmacy staff from community pharmacy services to other services or support. This includes formal referrals made by community pharmacy staff to other services, such as lifestyle weight management programs, social prescribing for debt management, or domestic violence helplines.</li><li>• Any type of signposting done by community pharmacy staff to other services or support.</li></ul>
Comparator	<ul style="list-style-type: none"><li>• No intervention.</li><li>• Any signposting or referral done by community pharmacy staff.</li></ul>

PICO Element	Details		
Outcomes	<i>Review question 4a</i>	<i>Review question 4b</i>	<i>Review question 4c</i>
	<ul style="list-style-type: none"> <li>Uptake of interventions or services to promote, maintain and improve health and wellbeing</li> </ul>	<ul style="list-style-type: none"> <li>Preference and experience of people using the service</li> </ul>	<ul style="list-style-type: none"> <li>Costs, savings and effectiveness               <ul style="list-style-type: none"> <li>Cost per quality adjusted life year</li> <li>Cost per unit of effect</li> <li>Net benefit</li> </ul> </li> </ul>

1 **Effectiveness evidence**

2 **Included studies**

3 Papers were included if they met the PICO and were:

- 4 • Randomised controlled trials, before and after studies, or any other type of  
5 comparative study design.
- 6 • Systematic reviews of randomised controlled trials or other comparative studies, if  
7 the majority of included studies met the PICO. If the majority of studies did not  
8 meet the PICO, individual studies included in the systematic review were  
9 considered separately for inclusion in this evidence review.
- 10 • Conducted in the UK, Australia, Canada, Republic of Ireland, the European Union  
11 (including Norway and Switzerland), New Zealand and Chile.
- 12 • Published between 1990 and 2016.
- 13 • Published in English language.

14 **Excluded studies**

15 Papers were excluded if they:

- 16 • Did not include comparative data, that is, they did not included data either  
17 comparing an intervention to another active intervention or a control intervention,  
18 or comparing data before and after an intervention.
- 19 • Were related to treatment of diseases and acute medical conditions, such as  
20 dispensing, other medicine or device services, self-care to improve the use of  
21 medicines or devices, urgent care.
- 22 • Were related to vaccinations.
- 23 • Only included interventions delivered by distance-selling (online) pharmacies.
- 24 • Only looked at the effectiveness of screening, checks and testing, such as blood  
25 glucose checks, blood pressure checks, cardiovascular risk assessments,  
26 cholesterol checks, medicine use reviews, mole checking services, NHS Health  
27 checks.
- 28 • Included interventions delivered by people other than community pharmacy staff.  
29 Studies that were delivered by a mixture of community pharmacy staff and other  
30 healthcare professionals were only included if results for the services provided by  
31 community pharmacy staff were reported separately.

33 See [appendix K](#) for full list of excluded studies

34  
35  
36  
37

1 **Summary of effectiveness studies included in the evidence review**

2 In total 14,652 references were found across the four review questions. Full-text papers of  
 3 361 citations seemed potentially relevant. In total 4 primary studies of effectiveness and 1  
 4 qualitative study was included in review 4.

5  
 6

**Table 2. Summary of the effectiveness evidence for signposting and referral**

Study	Setting and country	Intervention	Health area	Outcomes
Evans et al. (1997)	Community pharmacies	Advised to seek advice from elsewhere regardless of any changes in presenting symptoms	Any	Uptake of GP appointment
	South-East Wales, UK	Advised to seek advice only if presenting symptoms worsen or do not improve		
Michie et al. (2014)	Community pharmacies	Empty box of emergency contraception to take to family planning clinic	Sexual health	Uptake of appointment with sexual health clinic or other contraception provider
	Edinburgh, UK	Verbal and written advice on methods of contraception, including locations of family planning clinics		
Perraudin et al (2015)	Community pharmacies	Information brochure along with estimated risk of obstructive sleep apnea syndrome.	Obstructive Sleep Apnea Syndrome (OSAS)	Diagnostic test for OSAS
	France	Signed letter for GP referral for further diagnostic testing		
Sriram et al. (2016)	Community pharmacies	Referral letter to GP based on Jodi Lee Test and pharmacist opinion	Cancer awareness	Uptake of GP appointment
	Perth, Australia	Referral letter to GP based on pharmacist opinion		

7 See appendix D for full evidence tables.

8 **Synthesis and quality assessment of effectiveness evidence included in the**  
 9 **review**

10 Studies included in this review were a mix of experimental and observational study  
 11 designs. Studies with a control group were assessed for risk of bias using the Cochrane  
 12 Effective Practice and Organisation of Care (EPOC) checklist as referenced in Appendix  
 13 H of the [NICE methods manual](#). The Effective Public Health Practice Project (EPHPP) QA  
 14 Checklist was applied to assess risk of bias in uncontrolled before-and-after studies.

15  
 16 GRADE methodology was used to appraise the evidence across five potential sources of  
 17 uncertainty: risk of bias, indirectness, inconsistency, imprecision and other issues. Overall  
 18 ratings start at 'High' where the evidence comes from RCTs, and 'Low' for evidence  
 19 derived from observational studies. Meta-analysis was not undertaken within this review  
 20 and results are presented from single studies only, thus the inconsistency domain of  
 21 GRADE was largely not applicable. Details of how the evidence for each outcome was  
 22 appraised across each of the quality domains is given below.



1

Quality domain	Description
Risk of bias	<p>Limitations in study design and implementation may bias the estimates of the treatment effect. Major limitations in studies decrease the confidence in the estimate of the effect. Examples of such limitations are selection bias (often due to poor allocation concealment), performance and detection bias (often due to a lack of blinding of the patient, healthcare professional or assessor) and attrition bias (due to missing data causing systematic bias in the analysis). Where there are no study limitations, evidence is assessed as having 'no serious' risk of bias. Alternatively, evidence may be downgraded one level ('serious' risk of bias) or two levels ('very serious' risk of bias).</p>
Indirectness	<p>Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question. Where the evidence is directly applicable to the PICO, it is assessed as having 'no serious' risk of indirectness. Alternatively, evidence may be downgraded one level ('serious' risk of indirectness) or two levels ('very serious' risk of indirectness).</p>
Inconsistency	<p>Inconsistency refers to an unexplained heterogeneity of effect estimates between studies pooled in the same meta-analysis. The <math>I^2</math> statistic describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance). As meta-analysis was not performed within this review downgrading for inconsistency was not applicable.</p>
Imprecision	<p>Results are imprecise when studies include relatively few patients and few events (or highly variable measures) and thus have wide confidence intervals around the estimate of the effect relative to clinically important thresholds. 95% confidence intervals denote the possible range of locations of the true population effect at a 95% probability, and so wide confidence intervals may denote a result that is consistent with conflicting interpretations (for example a result may be consistent with both public health benefit AND public health harm) and thus be imprecise.</p> <p>Imprecision was assessed with reference to minimally important difference (MID) thresholds for individual outcomes (smallest change in an outcome that is considered important by patients or health care professionals). Established MIDs are published in previous literature and seen and accepted in clinical community. It was decided that the point measure would be used to decide whether or not the result was clinically important, and that the 95% confidence intervals would indicate certainty of this importance. Uncertainty is introduced where confidence intervals crossed the MID threshold. If the confidence interval crosses either the lower or upper MID threshold this indicates 'serious' risk of imprecision. Crossing both MID thresholds indicates 'very serious' risk of imprecision in the effect estimate. Default MIDs are used where no established MID's for individual outcomes are found (0.75 and 1.25 for dichotomous outcomes and <math>0.5 \times SD</math> of control group at baseline for continuous outcomes). If the MID could not be calculated (e.g. because standard deviation of outcome measure at baseline was not reported in the paper) then we downgraded by 1 level as it was 'not possible to calculate imprecision from the information reported in the study'. Where data was pooled in analyses, the study with the largest weight was used as the control group for MID calculations.</p> <p>Where the 95%CI does not cross either MID threshold, the evidence is assessed as having 'no serious' risk of imprecision unless the effect estimate is derived on the basis of few events and a small study sample (that is, less than 300 events for dichotomous outcomes or total sample size less than 400 for continuous outcomes). In that case the results were downgraded one level for 'serious' imprecision to reflect uncertainty in the effect estimate.</p>

Quality domain	Description
Other issues	<p>Publication bias is a systematic underestimate or overestimate of the underlying beneficial or harmful effect due to the selective publication of studies. A closely related phenomenon is where some papers fail to report an outcome that is inconclusive, thus leading to an overestimate of the effectiveness of that outcome.</p> <p>Sometimes randomisation may not adequately lead to group equivalence of confounders, and if so this may lead to bias, which should be taken into account. Potential conflicts of interest, often caused by excessive pharmaceutical company involvement in the publication of a study, should also be noted.</p>

1

2 Details of how the 4 main quality elements (risk of bias, indirectness, inconsistency and  
 3 imprecision) were appraised for each outcome are given below in the GRADE tables.  
 4 Publication or other bias was only taken into consideration in the quality assessment if it  
 5 was apparent.

6

GRADE rating	Description
High	Further research is very unlikely to change our confidence in the estimate of effect.
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very Low	Any estimate of effect is very uncertain.

7

See Appendix F for full GRADE tables.

8

The evidence from the effectiveness studies was all very low in quality. This is because all  
 9 of the included studies had either serious or very serious risk of bias and most of the  
 10 studies had serious indirectness and small numbers of events.

11

A summary of the quality of the evidence for each type of outcome is provided in table 3.

12

13

**Table 3. Summary of the quality of the evidence for each outcome for signposting and referral**

14

Outcome	Quality of evidence	
Uptake of services	Uptake of GP appointment	Very low
	Uptake of appointment with family planning clinic or other contraception provider	Very low
	Diagnostic test for obstructive sleep apnea syndrome	Very low

15

### Acceptability evidence

16

To assess the acceptability of providing signposting or referral services in community  
 17 pharmacy settings, the views and experiences of pharmacy service users were sought from  
 18 the qualitative literature.

19

### Included studies

Community Pharmacy: Evidence review 4 Signposting and referral (DRAFT, January 2018)

1 Studies were included if they sought out to determine the acceptability of providing  
 2 signposting or referral services to pharmacy users or explored how these types of  
 3 interventions could be made more acceptable to users of community pharmacy services.  
 4 Anyone who may use a community pharmacy was eligible for participation and specific  
 5 types of interventions providing formal referrals to other services such as lifestyle weight  
 6 management programs, debt management or domestic violence helplines were included.  
 7 Any type of signposting done by community pharmacy staff to other services or support  
 8 was also included. Outcomes of interest were respondent preferences and experience  
 9 and also quality of life. Data needed to be collected using either interviews (face to face,  
 10 telephone, SMS or online) or focus groups. Only studies conducted in the UK, Australia,  
 11 Canada and the Republic of Ireland were included. See Appendix A for full details of  
 12 review protocol.

### 13 **Summary of acceptability studies included in the evidence review**

14 One study conducted in the UK met the inclusion criteria. This study assessed the barriers  
 15 and facilitators of providing pharmacy based interventions to increase uptake of  
 16 emergency contraception.

17

First Author, Year	Design & Analysis	Country	Health Area	Population	Outcomes	Quality Rating
Michie, 2016	Face to face semi-structured interviews  Thematic analysis	UK	Sexual Health	12 female emergency contraceptive users	Acceptability Barriers & facilitators	+

18 **Michie (2016 [+])** conducted semi-structured face to face interviews with 12 females  
 19 (mean age 26 years) requiring emergency contraception about barriers and facilitators of  
 20 providing pharmacy based interventions to increase uptake of effective contraception  
 21 following emergency contraception. Themes around the usefulness and acceptability of  
 22 the approach were emerged.

### 23 **Quality assessment of acceptability studies included in the evidence review**

24 Included studies were rated individually to indicate their quality, based on assessment  
 25 using a checklist. The tool used to assess the quality of studies was selected from  
 26 appendix H in the methods manual. The quality ratings used for included studies are  
 27 outlined below:

28

++	All or most of the checklist criteria have been fulfilled, and where they have not been fulfilled the conclusions are Very unlikely to alter.
+	Some of the checklist criteria have been fulfilled, and where they have not been fulfilled, or are not adequately described, the conclusions are unlikely to alter.
-	Few or no checklist criteria have been fulfilled and the conclusions are likely or Very likely to alter.

29 The included acceptability study was of moderate quality due to limitations in the lack of  
 30 clarity on the role of the researcher and lack of rigour in data analyses. Subsequently

1 there are likely to be issues with the reliability of the findings and the conclusions may be  
2 inadequate.

### 3 **Economic evidence**

#### 4 **Included studies**

5 No studies on the cost effectiveness of information provision by community pharmacy staff  
6 were identified.

#### 7 **Excluded studies**

8 See [appendix K](#) for full list of excluded studies.

#### 9 **Economic model**

10 No new economic modelling was done for this review question

### 11 **Evidence statements**

#### 12 ***Evidence statement 4.1 – Advice to make a GP appointment based on presenting*** 13 ***symptoms increased uptake of GP appointments [GRADE profile 1]***

- 14 • Very low quality evidence from 1 observational cohort study with 40 participants found  
15 that asking participants to go to their GP based on presenting symptoms resulted in a  
16 clinically important increase in the number of participants attending the GP  
17 appointment compared to asking participants to go to their GP if presenting symptoms  
18 do not improve or get worse (RR 5.25, 95% CI 1.93 to 14.25).

#### 19 ***Evidence statement 4.2 – No evidence that referral to GP based on results of Jodi Lee*** 20 ***test for bowel cancer increased uptake of GP appointments [GRADE profile 1]***

- 21 • Very low quality evidence from 1 before and after study with 41 participants found that  
22 a standard referral letter after using the Jodi Lee test for bowel cancer symptoms may  
23 not increase the uptake of GP appointments compared to a standard referral letter  
24 based on pharmacist opinion of bowel cancer symptoms (RR 6.22, 95% CI 0.90 to  
25 43.09).

#### 26 ***Evidence statement 4.3 – Advice to attend family planning clinic using an empty box*** 27 ***of emergency contraception increased uptake of appointments with family planning*** 28 ***clinics or other contraception providers [GRADE profile 1]***

- 29 • Very low quality evidence from 1 randomised controlled trial with 61 participants found  
30 that asking participants to attend a family planning clinic with an empty box of  
31 emergency contraception resulted in a clinically important increase in the uptake of  
32 appointments at family planning clinics or other contraception providers compared to  
33 providing verbal and written advice on methods of contraception and locations of family  
34 planning clinics (RR 3.72, 95% CI 1.58 to 8.74).

#### 35 ***Evidence statement 4.4- Providing information brochures with advice and a written*** 36 ***referral to customers deemed to be at increased risk for obstructive sleep apnea*** 37 ***syndrome (OSAS) to consult with their GP increases uptake of OSAS diagnostic*** 38 ***testing [GRADE profile 1]***

- 39 • Very low quality evidence from one cohort study conducted in France with 782  
40 participants who were overweight or obese and on drug based antihypertensive  
41 therapy found that community pharmacists providing an information brochure, brief  
42 advice and a written referral to consult with a GP resulted in a clinically important  
43 increase uptake of diagnostic testing for OSAS (OR 2.24, 95% 1.25 to 4.01).

1 **Evidence statement 4.5 – No evidence was identified for what characteristics of the**  
2 **person delivering signposting and referral interventions affect their effectiveness**

- 3 • No evidence was identified that directly compares intervention delivered by different  
4 members of staff working for a community pharmacy.  
5

6 **Acceptability evidence statements**

7 **Evidence statement 4.6 Rapid referral programs to family planning clinics fills a health**  
8 **service provision gap for women requiring emergency contraception**

9 One UK study [+<sup>4</sup>] examining the barriers and facilitators of community pharmacists  
10 providing referrals to a family planning clinic to women requiring emergency contraception  
11 found that women cited difficulties in or reluctance to accessing GP services for  
12 emergency contraception and viewed referral from a community pharmacist as a vital  
13 service *“I don’t want to trouble my GP for minor health concerns so I prefer to self-*  
14 *medicate or go to the pharmacy across from where I live”*. Furthermore the possibility of  
15 having a rapid access appointment for contraception was welcomed and could potentially  
16 influence future contraception behaviour change especially if it enabled quicker access to  
17 consultations and potentially more specialist support *“Getting emergency contraception*  
18 *can kick start your brain to thinking about wanting to get on the pill or something”*

19 <sup>4</sup>. Michie 2016 [+]

20 **Evidence statement 4.7 There are mixed views on the appropriateness of community**  
21 **pharmacists providing short-term supplies of hormonal contraception**

22 One UK study [+<sup>4</sup>] examining the barriers and facilitators of community pharmacists  
23 providing a one month supply of progesterone only pills reported that some women found  
24 a one month supply of contraception to be a *“waste of time”* and indicated it could put  
25 women off using hormonal methods as a one month supply may not provide sufficient  
26 time to fully understand how their body would react or what the risks and benefits of using  
27 the product were. This was particularly highlighted by women who had no previous  
28 experience using hormonal contraception *“I think for women like me who have never tried*  
29 *hormones it is not a good idea”*. Some women also indicated there were questions they  
30 wanted to ask the community pharmacist but did not feel they were able and may have  
31 preferred to discuss options with a GP. Conversely some respondents indicated they felt  
32 speaking to a pharmacist was a good alternative *“as some people can be hesitant going*  
33 *on it and asking about it from their GP, so if they are offered they can try it. It is easier to*  
34 *ask the GP for more rather than to start on it”*. Women also thought that the time between  
35 presenting for emergency contraception and having an appointment would allow time to  
36 reflect on their experience and seek appropriate clinical and emotional support if needed.

37 <sup>4</sup>. Michie 2016 [+]

38 **Recommendations**

39 1.5.1 Ensure community pharmacies become health and wellbeing hubs within existing  
40 care and [referral](#) pathways. Do this by working with health and social care  
41 organisations including local authorities, clinical commissioning groups and  
42 health and wellbeing boards.

43 1.5.2 Consider establishing a formal referral process with other services, including GP  
44 services and those offered by organisations in the local government,  
45 community and voluntary sector:

- 1                                   • Consider basing pharmacy assessments, triage activities and referrals on  
2                                   agreed tools that support continuing treatment.  
3                                   • Consider designing triage activities to reduce multiple assessments and  
4                                   waiting times, for example by providing access to alcohol services after  
5                                   identifying harmful and dependent alcohol consumption using the AUDIT  
6                                   tool (or another threshold used locally).  
7  
8           1.5.3 Consider referring people to other services and triage within the agreed local care or  
9                                   referral pathway to give fast access to an appointment if needed. For example  
10                                  refer to:
- 11                                  • GPs or other healthcare providers for:
- 12                                   - an Intrauterine device service if they have asked for emergency  
13                                   hormonal contraception  
14                                   - assessment for sleep apnoea if agreed local assessment tools are in  
15                                   place  
16                                   - specialist support for high risk or dependent alcohol consumption  
17                                   - drug misuse services  
18                                   - weight reduction services
- 19                                  • local authority, NHS or community and voluntary sector organisations for:
- 20                                   - weight loss programmes  
21                                   - mental health support  
22                                   - drug misuse recovery support
- 23                                  • social services for home support.
- 24           1.5.4 When making a formal referral to another service, explain to the person why they are  
25                                  being referred, where they are being referred to and the service they can expect.  
26                                  Provide them with written information about the service if it is available.
- 27           1.5.5 When the pharmacy accepts a formal referral from another service:
- 28                                  • ensure the pharmacy has been given all relevant information so that care can  
29                                  start at the first opportunity  
30                                  • offer care as a walk-in service or, if this is not available or suitable, agree an  
31                                  appointment time and date with the person and give them the name of the  
32                                  staff member they will see.

### 33   **Signposting**

- 34           1.5.6 If the community pharmacy cannot provide support for specific needs or offer a formal  
35                                  referral, signpost people to other local services. For example:
- 36                                  • specialist stop smoking services  
37                                  • social care services for people using needle and syringe programmes  
38                                  provided by the pharmacy  
39                                  • other community services such as Citizens' Advice Bureau, housing or  
40                                  benefits advice, employment and fire safety advice  
41                                  • government and third sector debt advice websites.

## 1 Evidence discussion

### 2 Interpreting the evidence

#### 3 *The outcomes that matter most*

4 The committee agreed that uptake of interventions or services to promote, maintain and  
5 improve health and wellbeing was a critical outcome for this review. Four out of five  
6 effectiveness studies addressed either the uptake of GP appointments or the uptake of an  
7 appointment with a family planning clinic or other contraception provider [ES 4.1-4.3]. Health  
8 areas these studies targeted included sexual health, cancer awareness and overall health.  
9 One effectiveness study assessed the uptake of obstructive sleep apnea syndrome (OSAS)  
10 diagnostic testing in those at risk who were referred to a GP by a pharmacist [ES 4.4]. No  
11 evidence was identified which investigated the cost effectiveness of interventions within this  
12 review.

13 One qualitative UK studies assessed the general public's views on the acceptability of  
14 pharmacists providing signposting or referral services. The committee agreed that the views  
15 and experiences of pharmacy service users and the perceived barriers and facilitators of  
16 providing pharmacy based interventions to increase uptake of referrals were both important  
17 outcomes [ES 4.6].

18 The committee acknowledged that no evidence was identified that directly considered  
19 variations in the effectiveness of interventions by the characteristics of the person delivering  
20 it, the format of the intervention, or the characteristics of the person receiving it [ES 4.5].

#### 21 *The quality of the evidence*

22 There is evidence from only 4 effectiveness studies. Of these studies, one was carried out in  
23 France and one in Australia. Both qualitative studies were conducted in the UK. Seven  
24 evidence statements were generated across this review which were related to a range of  
25 health areas including sexual health, OSAS, cancer awareness and overall health [ES 4.1-  
26 4.8].

27 The committee agreed that the certainty in the effectiveness evidence was very low due to  
28 the high risk of bias and small number of events. Three effectiveness studies had fewer than  
29 100 participants overall [ES 4.1-4.3]. One study found the provision of information brochures  
30 with advice and a written referral to a GP to be effective in increasing diagnostic testing  
31 amongst 783 subjects who were risk of OSAS [ES 4.4]. The committee agreed that as other  
32 evidence within this area was limited, the intervention should be given as an example to  
33 underpin a more generalised recommendation about how community pharmacies ought to  
34 work alongside other health care services to integrally support improved health and well-  
35 being. The committee noted that the evidence indicated patients are more likely to make an  
36 appointment with their GP if a pharmacist spends time with the person explaining the  
37 importance and relevance of the service being referred to.

38 The committee agreed that the UK study was not relevant to the guideline [ES 4.1]. The  
39 study was an old, retrospective study designed to determine whether pharmacists should  
40 give 'watch and wait' advice, rather than which forms of referral or signposting are effective.  
41 Although this study was not powered to show any harm the committee felt that practise within  
42 community pharmacies has changed substantially since publication of the study and  
43 therefore it should not be used to inform a recommendation.

44 The committee acknowledged that the study from Australia may not apply to the UK [ES 4.2].  
45 It covered bowel cancer screening for all those aged 18 and over rather than older people. In  
46 addition, it was not clear whether the screening tool used had been validated, and, more  
47 importantly, whether it has been validated in the UK. The committee noted that there is a  
48 national GP programme for bowel cancer screening in the UK where eligible people are



1 invited, and therefore it may not be something for community pharmacies to deliver. Despite  
2 this the committee agreed that pharmacy staff should raise awareness of cancer screening  
3 services where appropriate.

4 The committee noted that 1 study of very low quality indicated that referral is more effective  
5 for increasing uptake of appointments than signposting. Evidence from one study suggested  
6 that using a token to refer people to other services could increase uptake of those services.  
7 For example, asking participants to attend a family planning clinic with an empty box of  
8 emergency contraception increased the uptake of appointments compared to providing  
9 verbal and written advice on methods of contraception and locations of family planning clinics  
10 [ES 4.3]. The committee agreed that having a formal referral process in place rather than a  
11 token per se that was the plausible mechanism of action and made recommendations in light  
12 of this.

13 The committee noted the usefulness and acceptability of UK pharmacy based interventions  
14 to increase uptake of effective contraception following emergency contraception. Rapid  
15 referral programs to family planning may fill a service provision gap for women requiring  
16 emergency contraception as they were viewed as a vital service [ES 4.6]. However there  
17 were mixed views on the appropriateness of community pharmacists providing short-term  
18 supplies of hormonal contraception, as some women agreed that a one month supply may  
19 not provide sufficient time to fully understand the personal suitability of the product or the  
20 risks and benefits of using it [ES 4.7]. The committee noted that the acceptability evidence  
21 had limitations in regard to the lack of clarity on the role of the researcher, lack of rigour in  
22 data analyses and the lack of detailed verbatim.

### 23 ***Advantages and disadvantages of providing referral and signposting***

24 The committee acknowledged that there was a paucity of evidence within this area. A  
25 number of studies indicated that referral and explaining the importance of accepting referrals  
26 to other services were effective and acceptable, but the lack of quality and consistency  
27 reduced the overall certainty in the evidence [ES 4.1-4.6]. However, they did agree that  
28 community pharmacy should become health and wellbeing hubs as part of the local care  
29 network, increasing the likelihood of referral processes being in place and thus improving  
30 outcome for patients. Integrating community pharmacies into the care pathway is in line with  
31 the integration of health and care through the NHS sustainability and transformation  
32 partnerships (STPs) and the Five Year Forward View.

33 The committee agreed that some evidence indicated that referral by community pharmacy  
34 teams increased service uptake more than signposting, however there was not enough  
35 evidence to strongly recommend how to effectively refer in and out of pharmacies to improve  
36 patient outcomes. It was noted that if community pharmacies do offer such a service it would  
37 need to match that provided by GPs and other services, which would mean fast referrals for  
38 those in need and ensuring people referred on are not re-assessed when they enter the care  
39 pathway. The committee decided to provide examples of the types of issues that community  
40 pharmacists could make referrals on, based on the evidence of effect as well as their expert  
41 opinion.

42 The committee noted that the evidence suggested there were no direct harms or  
43 disadvantages of delivering referral and signposting within community pharmacy settings and  
44 therefore should be considered as an important approach to improving health and well-being  
45 in individuals, particularly those who may not access healthcare elsewhere such as  
46 underserved groups or those from deprived communities. The committee agreed that further  
47 research to support the effectiveness and cost effectiveness of formal referrals within  
48 community pharmacies would strengthen the current evidence base.

### 49 **Cost effectiveness and resource use**



1 No cost effectiveness evidence was identified for this review

2 The committee noted that ensuring community pharmacies become health and wellbeing  
3 hubs within existing care pathways is in line with the transformational work that is being  
4 pushed across England to integrate health and care services through sustainability and  
5 transformation partnerships (STPs). The integration of health care services is also one of the  
6 models of care in the NHS overall Five Year Forward View. The committee noted that  
7 establishing links with other health and care organisations may result in upfront costs such  
8 as the time it takes to develop pathways and the time it takes to make a referral. However it  
9 was agreed that this may be offset by several downstream benefits including more efficient  
10 use of resources in the wider system, better continuity of care and quicker access to the right  
11 treatment for some groups who do not access health services elsewhere (such as those from  
12 underserved or underprivileged communities).

### 13 **Other factors the committee took in to account**

14 Expert testimony on the vision for community pharmacy based on the The Community  
15 Pharmacy Forward View (CPFV), published in September 2017 (<https://cpfv.info/>) was used  
16 to provide context and future proofing for the recommendations [EP 6]. Testimony revealed  
17 the need for community pharmacy to have greater consistency to effectively support the  
18 overall health and social care system. Three core domains were laid out during the testimony  
19 that describe the future role of community pharmacy. This included the facilitator of  
20 personalised care for people with long-term conditions, the trusted, convenient first point of  
21 call for episodic healthcare advice and treatment and the neighbourhood health and  
22 wellbeing hub. In light of this, the committee agreed to recommend that all community  
23 pharmacies operate and are recognised as health and wellbeing hubs, providing the 'go-to'  
24 location for support, advice and resources on staying well and independent.

25 The committee acknowledged that the referral process may work two ways within a  
26 community pharmacy. Members of the public may be referred in to a pharmacy from an  
27 external healthcare provider, or they may be referred to an external service by a pharmacy  
28 team. Expertise on local community pharmacy health services in the North Manchester  
29 region [EP 4] revealed the importance of including community pharmacy in to existing care  
30 pathways where formal referral links with other health and care providers are established and  
31 consistently managed. Based on their expert opinion, the committee agreed that community  
32 pharmacy teams should consider being involved in formal referrals to other organisations for  
33 broader health and wellbeing support as some people will benefit from particular services  
34 that are not available in the pharmacy. They noted that having a seamless service model in  
35 place will ensure effective continuity of care, improved efficiency of services and will result in  
36 better outcomes for the local population.

37 The committee noted that where an effective agreed referral process with another provider is  
38 not in place, signposting to other may still be important, but should, however not be  
39 recommended as usual practise.

40 The committee recognised that social prescribing would be an important concept to consider  
41 when signposting and referring within pharmacies. However, the committee were unable to  
42 recommend this specifically as the concept is very complex where evidence in regard to its  
43 effectiveness or acceptability within these settings is limited. Although there is not yet a  
44 universally agreed definition of what this term means, it may be described as a process  
45 whereby health care professionals refer individuals to non-clinical services within the  
46 community which may help improve health and well-being. The committee considered it an  
47 area for further evaluation and thus made a research recommendation on how it may be of  
48 benefit within pharmacy referrals.

### 49 **Linked expert testimony ([see appendix M](#))**

- 1 EP 4 – Expert Paper 4 – Community Pharmacy to promote health and well-being
- 2 EP 6 – Expert Paper 6 – Five year forward view for Pharmacy
- 3

# Appendices

## Appendix A – Review protocols

A number of elements within the protocols are common across two or more of the review questions. To reduce repetition these details have been included below the protocols, and will not be repeated in each protocol.

The elements common across reviews 1 to 4 are:

- Eligibility criteria - population
- Eligibility criteria - interventions
- Eligibility criteria - comparators
- Outcomes and prioritisation
- Eligibility criteria - study design
- Other inclusion or exclusion criteria
- Selection process - duplicate screening
- Data management (software)
- Information sources - databases and dates
- Methods for assessing bias at outcome or study level

See common elements across reviews 1 to 4 for more details.

### Review question 4a - Effectiveness of signposting and referral

Field	Content
Review question 4a	What is the most effective way for community pharmacies to refer or signpost people to other services or support?
Type of review question	Intervention
Objective of the review	<p>This review aims to determine the most effective way for community pharmacy staff to refer or signpost people from community pharmacy to other services or support.</p> <p>The review will also explore whether effectiveness varies by the characteristics of the intervention, the person delivering the intervention, or the person receiving the intervention.</p>
Eligibility criteria - population	<p>Anyone who may use community pharmacy services</p> <p>See common elements section for further details</p>
Eligibility criteria - interventions	<p>Any type of referral made by community pharmacy staff from community pharmacy services to other services or support. This includes formal referrals made by community pharmacy staff to other services, such as lifestyle weight management programs, social prescribing for debt management, or domestic violence helplines.</p> <p>Any type of signposting done by community pharmacy staff to other services or support.</p>

Field	Content
	<p>Exclusions:</p> <ul style="list-style-type: none"> <li>• Studies of the effectiveness of the services or support that the person is referred or signposted to.</li> <li>• Interventions delivered by anyone who is not working for a community pharmacy</li> <li>• Interventions delivered by distance-selling (online) pharmacies</li> </ul> <p>See common elements section for further details</p>
Eligibility criteria - comparators	<p>No intervention.</p> <p>Any signposting or referral done by community pharmacy staff.</p> <p>See common elements section for further details.</p>
Outcomes and prioritisation	<p>1 Uptake of interventions or services to promote, maintain and improve health and wellbeing</p> <p>See common elements section for further details.</p>
Eligibility criteria – study design	<ul style="list-style-type: none"> <li>• Systematic reviews of studies of effectiveness</li> <li>• Studies of effectiveness, including: <ul style="list-style-type: none"> <li>○ Randomised controlled trials</li> <li>○ Quasi-experimental studies, such as non-randomised controlled trials and before and after studies</li> </ul> </li> </ul> <p>See common elements section for further details.</p>
Other inclusion or exclusion criteria	<p>Only papers published in English will be included.</p> <p>Only studies undertaken in the UK, Australia, Canada and Republic of Ireland will be included.</p> <p>See common elements section for further details.</p> <p>March 15, 2017: The committee requested that in addition to the initially agreed 4 countries the effectiveness review be expanded to include studies from the European Union (including Norway and Switzerland), New Zealand and Chile. Change approved by NICE QA on March 28, 2017</p>
Proposed sensitivity or subgroup analysis	<p>Where evidence allows, the review will also answer the following sub questions:</p> <ol style="list-style-type: none"> <li>I. What characteristics of the person delivering the intervention (for example their job role and competencies, or being a health champion) affect its effectiveness in community pharmacy?</li> <li>II. How does the way the intervention is delivered, for example, the medium used, when, how often, or where the intervention takes place (such as in a consultation room, over the counter, in someone's home, or electronic communication) affect its effectiveness in community pharmacy?</li> <li>III. What characteristics of the people receiving the intervention (for example, age or gender) affect its effectiveness in community pharmacy?</li> </ol> <p>Subgroup analysis by the health area (for example, physical activity, smoking cessation) may be undertaken, if appropriate.</p>

<b>Field</b>	<b>Content</b>
Selection process – duplicate screening	See common elements section for details.
Data management (software)	See common elements section for details.
Information sources – databases and dates	See common elements section for details.
Methods for assessing bias at outcome or study level	See common elements section for details.
Criteria for quantitative synthesis	For details please see section 6.4 of Developing NICE guidelines: the manual
Methods for quantitative analysis – combining studies and exploring inconsistency	Data from different studies will be meta-analysed if the studies are similar enough in terms of interventions, comparators and outcomes.
Meta-bias assessment- publication bias, selective reporting bias	For details please see section 6.2 of Developing NICE guidelines: the manual.
Confidence in cumulative evidence	For details please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual
Review staff	Rachel Walsh (Technical Analyst) Ella Novakovic (Senior Technical Analyst) Daniel Tuvey (Information Specialist)

#### **Review question 4b - Acceptability of signposting and referral**

<b>Field</b>	<b>Content</b>
Review question 4b	Is offering signposting and referral acceptable to users of community pharmacy services?
Type of review question	Views and experiences
Objective of the review	The review aims to determine whether offering signposting and referral is acceptable to users of community pharmacy services. It will also explore how interventions could be made more acceptable to users of community pharmacy services.
Eligibility criteria - population	Anyone who may use community pharmacy services  See common elements section for further details

Eligibility criteria - interventions	<p>Any type of referral made by community pharmacy staff from community pharmacy services to other services or support. This includes formal referrals made by community pharmacy staff to other services, such as lifestyle weight management programs, social prescribing for debt management, or domestic violence helplines.</p> <p>Any type of signposting done by community pharmacy staff to other services or support.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> <li>• Studies of the effectiveness of the services or support that the person is referred or signposted to.</li> <li>• Interventions delivered by anyone who is not working for a community pharmacy</li> <li>• Interventions delivered by distance-selling (online) pharmacies</li> </ul> <p>See common elements section for further details.</p>
Eligibility criteria - comparators	<p>No intervention.</p> <p>Any signposting or referral done by community pharmacy staff.</p> <p>See common elements section for further details.</p>
Outcomes and prioritisation	<p>Preference and experience of people using the service</p> <p>See common elements section for further details.</p>
Eligibility criteria – study design	<p>Interviews – unstructured and semi-structured (face to face, via telephone or SMS, or online).</p> <p>Focus groups.</p> <p>See common elements section for further details.</p>
Other inclusion or exclusion criteria	<p>Only studies undertaken in the UK, Australia, Canada and Republic of Ireland will be included.</p> <p>Only studies published in English will be included.</p> <p>See common elements section for further details.</p>
Proposed sensitivity or subgroup analyses	<p>Where evidence allows, the review will also answer the following sub question:</p> <p style="padding-left: 40px;">I. How can signposting and referral be made more acceptable to users of community pharmacy services?</p> <p>Subgroup analysis by the health area (for example, physical activity, smoking cessation) may be undertaken, if appropriate.</p>
Selection process – duplicate screening	<p>See common elements section for details.</p>
Data management (software)	<p>See common elements section for details.</p>
Information sources –	<p>See common elements section for details.</p>

databases and dates	
Methods for assessing bias at outcome or study level	See common elements section for details.
Criteria for qualitative synthesis	For details please see section 6.4 of Developing NICE guidelines: the manual
Methods for qualitative analysis – combining studies and exploring inconsistency	Data from different studies will be summarised using narrative synthesis.
Meta-bias assessment- publication bias, selective reporting bias	For details please see section 6.2 of Developing NICE guidelines: the manual.
Confidence in cumulative evidence	For details please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual
Review staff	Rachel Walsh (Technical Analyst) Ella Novakovic (Senior Technical Analyst) Daniel Tuvey (Information Specialist)

#### Review question 4c - Cost effectiveness of signposting or referral

Field	Content
Review question 4c	What is the most cost effective way for community pharmacies to refer or signpost people to other services or support?
Type of review question	Cost effectiveness
Objective of the review	This review aims to determine the most cost effective way for community pharmacy staff to refer or signpost people from community pharmacy to other services or support.  The review will also explore whether cost effectiveness varies by the characteristics of the intervention, the person delivering the intervention, or the person receiving the intervention.
Eligibility criteria - population	Anyone who may use community pharmacy services  See common elements section for further details.
Eligibility criteria - interventions	Any type of referral made by community pharmacy staff from community pharmacy services to other services or support. This includes formal referrals made by community pharmacy staff to other services, such as lifestyle weight management programs, social prescribing for debt management, or domestic violence helplines.

Field	Content
	<p>Any type of signposting done by community pharmacy staff to other services or support.</p> <p>Exclusions:</p> <ul style="list-style-type: none"> <li>• Studies of the effectiveness of the services or support that the person is referred or signposted to.</li> <li>• Interventions delivered by anyone who is not working for a community pharmacy</li> <li>• Interventions delivered by distance-selling (online) pharmacies</li> </ul> <p>See common elements section for further details.</p>
Eligibility criteria - comparators	<p>No intervention.</p> <p>Any signposting or referral done by community pharmacy staff.</p> <p>See common elements section for further details.</p>
Outcomes and prioritisation	<p>Costs, savings and cost effectiveness</p> <ul style="list-style-type: none"> <li>• Cost per quality adjusted life year</li> <li>• Cost per unit of effect</li> <li>• Net benefit</li> </ul> <p>See common elements section for further details.</p>
Eligibility criteria – study design	<ul style="list-style-type: none"> <li>• Systematic reviews of cost-effectiveness studies</li> <li>• Economic evaluations</li> <li>• Cost-utility studies</li> <li>• Cost benefit studies</li> <li>• Cost-effectiveness studies</li> <li>• Cost minimisation studies</li> <li>• Cost-consequence studies</li> </ul> <p>See common elements section for further details.</p>
Other inclusion or exclusion criteria	<p>Only papers published in English will be included.</p> <p>Only studies undertaken in the UK, Australia, Canada and Republic of Ireland will be included.</p> <p>See common elements section for further details.</p>
Proposed sensitivity or subgroup analysis	<p>Where evidence allows, the review will also answer the following sub questions:</p> <ol style="list-style-type: none"> <li>I. What characteristics of the person delivering the intervention (for example their job role and competencies, or being a health champion) affect its cost effectiveness in community pharmacy?</li> <li>II. How does the way the intervention is delivered, for example, the medium used, when, how often, or where the intervention takes place (such as in a consultation room, over the counter, in someone's home, or electronic communication) affect its cost effectiveness in community pharmacy?</li> <li>III. What characteristics of the people receiving the intervention (for example, age or gender) affect its cost effectiveness in community pharmacy?</li> </ol> <p>Subgroup analysis by the health area (for example, physical activity, smoking cessation) may be undertaken, if appropriate.</p>



<b>Field</b>	<b>Content</b>
Selection process – duplicate screening	See common elements section for details.
Data management (software)	See common elements section for details.
Information sources – databases and dates	See common elements section for details.
Methods for assessing bias at outcome or study level	See common elements section for details.
Criteria for quantitative synthesis	For details please see section 6.4 of Developing NICE guidelines: the manual
Methods for quantitative analysis – combining studies and exploring inconsistency	Data from different studies will be meta-analysed if the studies are similar enough in terms of interventions, comparators and outcomes.
Meta-bias assessment- publication bias, selective reporting bias	For details please see section 6.2 of Developing NICE guidelines: the manual.
Confidence in cumulative evidence	For details please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual
Review staff	Ella Novakovic (Senior Technical Analyst) Daniel Tuvey (Information Specialist)

### **Common elements across reviews 1 to 4**

The following aspects are common across two or more of the review questions.

#### ***Eligibility criteria - population***

Studies of people who have access to or are using community pharmacy services in any setting are included. This means that studies of people using community pharmacy services in commercial settings (such as high streets or supermarkets), healthcare settings (such as general practices), or community settings (such as care homes, places of worship) will be included. Studies of community pharmacy services provided in any area, including healthy new towns, will be included.

Studies of people using community pharmacy services in their own home, for example, if community pharmacy staff deliver medicines to their home, will be included.

Studies of people using distance selling pharmacies (also known as online pharmacies) will be excluded from this review.

#### ***Eligibility criteria - interventions***

### *Inclusions*

Studies of interventions delivered by community pharmacy staff will be included. This includes studies of interventions provided outside of a community pharmacy premises if the intervention is provided by community pharmacy staff. For example, a study of leaflets provided by community pharmacy staff in a place of worship would be included. Studies of interventions provided by staff who are not community pharmacy staff will be excluded, even if the intervention is delivered in community pharmacy premises. For example, a study of an intervention delivered by a GP that has rented a room in a community pharmacy but is working as an out of hour's service would be excluded. Studies that describe public health interventions provided by a 'clinical pharmacist' will be included if these studies were performed in a community pharmacy setting. Studies of interventions delivered by pharmacy students, within a community pharmacy setting, will be included.

Studies of health promotion campaigns from NHS England and Public Health England (such as Change4Life, One You, Eatwell Guide) will be included if they are delivered by community pharmacy staff. Studies of other initiatives, such as Men's Health Week, will be included if they are delivered by community pharmacy staff.

Studies of interventions that provide checks and testing to monitor the outcomes of interventions as part of behavioural support will be included in review 3.

Studies of any type of signposting and referral by community pharmacy staff to other services or support will be included in review 4. This includes:

- studies of signposting and referral to services or support offered by other NHS services, such as NHS stop smoking services
- studies of signposting and referral to services or support offered by non-NHS services, such as those provided by charity organisations
- studies of signposting and referral to other community pharmacies that offer services that are not available at the community pharmacy that the person presented to, such as chlamydia screening

Studies of signposting or referral to any service or support by community pharmacy staff will be included in review 4. This may include:

- disease management programs
- lifestyle weight management programs
- alcohol treatment services
- substance misuse services, including self-help groups
- sexual health services, including STI clinics and services that offer full range of contraceptive methods
- support services for smoking cessation, such as NHS Stop Smoking services
- social prescribing for debt management, domestic violence helplines, housing support, befriending.

### *Exclusions*

The effectiveness of screening, checks and testing will not be assessed in this review. This includes the effectiveness of:

- blood glucose checks
- blood pressure checks
- cardiovascular risk assessments
- cholesterol checks (including point of care tests)

- medicine use reviews
- mole checking services
- NHS Health Checks

NICE is unable to make recommendations on screening as these are provided by the National Screening Committee. Studies that look at the effectiveness of health promotion information and advice provided during screening (such as lifestyle advice), checks or testing will be included.

Studies of vaccinations will not be included in this review. Recommendations on vaccinations are provided by other NICE guidelines, such as Flu vaccination – increasing uptake (in development) and Immunisations: reducing differences in uptake in under 19s (PH21). Studies that look at the effectiveness of health promotion information and advice provided during a vaccination appointment, such as advice on sunlight exposure for people receiving vaccinations for travel abroad, will be included.

Studies of interventions provided by people who are not community pharmacy staff will be excluded. For example, studies of leaflets provided by district nurses would be excluded. Studies of interventions provided by pharmacy students, outside of the community pharmacy setting will be excluded. For example, an educational seminar led by pharmacy students directed at peers would be excluded.

Studies of interventions that are delivered in part by community pharmacy staff and in part by other healthcare professionals, such as GPs, will only be included if the study reports the results for community pharmacy staff separately. If results are not presented separately for community pharmacy staff then the study will not be included.

### **Health areas**

Studies of interventions in any health area will be included. This includes the following health areas:

- alcohol use, including:
  - alcohol misuse
  - recommended levels of alcohol consumption
- cancer awareness (all cancers), including:
  - risks and benefits of behaviours including:
    - sunlight exposure
    - use of sun care products
    - approaches to protecting skin (clothing, shade and sunscreen)
  - early signs and symptoms of any cancer, such as blood in urine or stools
- cardiovascular disease prevention, including:
  - lifestyle factors
- diabetes prevention, including:
  - lifestyle factors
  - healthy eating
  - physical activity
- substance misuse prevention, including:
  - needle and syringe exchange programmes, including disposal and injecting equipment
  - harm reduction services, including advice on safer injecting practices

- provision of, or access to services for, blood-borne virus testing, and treatment, including hepatitis B, hepatitis C and HIV
- falls prevention including:
  - correctly fitted footwear
  - using handrails
  - hydration and diet
  - physical activity
- mental health and wellbeing, including
  - getting a good night's sleep
  - physical activity in green spaces, such as how and where to do this locally
- orthopaedic conditions (such as osteoporosis, osteoarthritis and lower back pain), including:
  - physical activity
  - diet
- sexual health, including:
  - emergency contraception
  - safer sex practice, including use of condoms
  - methods of contraception
  - preventing unwanted pregnancies
  - pregnancy testing
  - sexually transmitted infections, including testing
  - information on HIV testing
- smoking and smokeless tobacco, including:
  - stopping use
  - harm reduction
  - nicotine-containing products
  - the importance of smoke free homes
- weight management, including:
  - maintaining a healthy weight
    - why maintaining a healthy weight is beneficial
    - how to maintain a healthy weight
    - checking weight
  - nutrition:
    - healthy eating
    - vitamin D
    - sugar
    - salt
    - saturated fat
    - folic acid
    - child and maternal health
  - physical activity
    - benefits of physical activity
    - appropriate local opportunities to be more active
    - recommended levels of physical activity

- weight reduction programmes
  - over the counter weight management products
  - healthy eating
  - physical activity

### **Eligibility criteria - comparators**

Studies with comparators provided outside of a community pharmacy premises are to be included only if the comparator is provided by community pharmacy staff. For example, a study that uses leaflets provided by community pharmacy staff in a place of worship as a comparator would be included.

Studies with comparators that are delivered in part by community pharmacy staff and in part by other healthcare professionals, such as GPs, will only be included if the study reports the results for interventions delivered by community pharmacy staff separately. If results are not presented separately for interventions delivered by community pharmacy staff then the study will not be included.

Studies that compare the effectiveness of different types of community pharmacy staff to deliver an intervention will be included. For example, studies that compare leaflets provided by community pharmacy staff who are health champions to leaflets provided by community pharmacy staff who are not health champions.

Studies that compare the way the intervention is delivered will be included. For example, studies that compare face to face with electronic communication, or studies that compare one-off interventions to interventions delivered at every contact with staff, will be included.

Studies that compare the effectiveness of interventions in different groups of people using community pharmacy services will be included. For example, studies comparing the effectiveness of self-help booklets in men and women would be included.

### **Outcomes and prioritisation**

Health outcomes may include clinical measurements, such as physiological and biochemical measures related to risk factors, such as blood pressure, body mass index, or blood glucose levels. It may also include mortality.

Examples of actions include behavioural outcomes such as smoking cessation or changes to levels of physical activity. It can include uptake, continuation and completion of services. 'Action' also includes intermediary steps to enacting a healthier behaviour, such as picking up a leaflet.

Studies may report patient activation, which refers to the knowledge, skills and confidence a person has in managing their own healthcare. Patient activation will be included as an outcome in the existing outcomes listed in the review protocols above.

Outcomes with longer timescales will be prioritised over shorter outcomes, e.g. body mass index at 12 months will be prioritised over body mass index at 3 months.

See table i. for the prioritisation and minimal important differences for each outcome in review questions 1a, 2a, 3a and 4a. These will be used to inform the GRADE profiles.

**Table i. Prioritisation and minimal important difference for each outcome**

<b>Outcome</b>	<b>Priority</b>	<b>Minimal important difference</b>
<b>Review question 1a (information and awareness raising)</b>		
Action	Critical	25% point change in relative risk
Intention	Important	25% point change in relative risk

Attitudes	Important	25% point change in relative risk
Knowledge	Important	25% point change in relative risk
Awareness	Important	25% point change in relative risk
<b>Review questions 2a (advice or education) and 3a (behavioural support)</b>		
Clinical measurements or health outcomes	Critical	25% point change in relative risk
Action	Critical	25% point change in relative risk
Intention	Important	25% point change in relative risk
Attitudes	Important	25% point change in relative risk
Knowledge	Important	25% point change in relative risk
Awareness	Important	25% point change in relative risk
Wellbeing	Less important	25% point change in relative risk
Quality of life	Less important	25% point change in relative risk
<b>Review question 4a (signposting and referral)</b>		
Uptake of interventions or services to promote, maintain and improve health and wellbeing	Critical	25% point change in relative risk

### **Eligibility criteria - study design**

Systematic reviews will only be included if the review question in the paper matches the review question in the evidence review for the guideline. Systematic reviews that do not answer a review question of interest may be used for citation searching if primary searches do not yield a substantial amount of evidence. Systematic reviews must have clear inclusion/exclusion criteria and report critical appraisal of included studies to be included.

For review questions 1a, 2a, 3a and 4a (effectiveness) primary studies will only be included if they are comparative. This includes:

- Studies that compare a group that receives an intervention to another group that does not receive an intervention,
- Studies that compare a group that receives an intervention to another group that receives a different intervention,
- Studies that compare the same group before and after an intervention.

Studies that compare the same intervention in different groups will be included to answer the sub question on whether the characteristics of the people receiving an intervention (for example, age or gender) affect its effectiveness.

Qualitative studies that relate to interventions of interest will be included for data on quality of life and preference and experience of people using the services. Only qualitative studies from the UK, Australia, Canada and the Republic of Ireland., will be included.

In the event of more evidence being identified than is feasible to consider in the time available, priority will be given to using RCTs and nRCTs to identify data for comparative outcomes.

The following types of papers will not be included:

- Non-systematic literature reviews
- Case-control studies
- Cross-sectional studies
- Quantitative surveys
- Study protocols
- Opinion pieces

- Commentaries
- Editorials
- Letters

### ***Other inclusion or exclusion criteria***

The committee agreed that Australia, Canada and the Republic of Ireland, have community pharmacy services that are similar enough to the UK that studies from these countries can be used to make recommendations for UK practice. On March 15, 2017 the committee requested that in addition to the initially agreed 4 countries the effectiveness review be expanded to include studies from the European Union (including Norway and Switzerland), New Zealand and Chile. This change was approved by NICE QA on March 28, 2017. The committee felt that the community pharmacy services in other countries are too dissimilar to the UK to allow evidence from those countries to be used to make recommendations for UK practice.

### ***Selection process - duplicate screening***

10% of the search results will be blind-screened by a second reviewer. Any disagreements will be resolved by the two reviewers, and escalated to a third reviewer if agreement cannot be reached. If the initial level of agreement is below 90%, a second round of blind-screening will be considered.

All data extraction and critical appraisal will be checked by a second reviewer. Any disagreements will be resolved by the two reviewers, and escalated to a third reviewer if agreement cannot be reached.

In the event of more evidence being identified than is feasible to consider in the time available, priority will be given to:

- evidence with critical or highly important outcomes
- number of participants (n>100) or number of sites in the study.

These criteria were agreed by the committee at the Public Health Advisory Committee (PHAC) 0, however, further discussion of the criteria with PHAC will take place if necessary.

A date cut off of the year 1990 will be used. This is because this is when the National Health Service and Community Care Act 1990 was put in place and health authorities were given responsibility for managing their own budgets. Using 1990 is also consistent with the date that is used in the review question on pharmacists in the Acute Medical Emergencies in adults and young people services guidance that is currently in development by NICE.

### ***Data management (software)***

EPPI Reviewer will be used:

- to store lists of citations
- to sift studies based on title and abstract
- to record decisions about full text papers
- to store extracted data.

If meta-analysis is undertaken, Cochrane Review Manager 5 will be used to perform the analysis.

Qualitative data will be analysed using EPPI Reviewer. Qualitative data will be summarised using GRADE-CERQUAL (if appropriate) or narrative synthesis.

**Information sources - databases and dates**

The following sources will be searched:

- Medline
- Embase
- Cochrane Library
- PsycINFO
- Cinahl
- ASSIA
- EconLit
- EconPapers
- PharmLine
- Health Services Research in Pharmacy Practice

The following grey literature sources will also be searched:

- Social policy and practice
- NIHR journals library
- Academic centres (Pharmacy Schools): Aston, Bath, Birmingham, Bradford, Brighton, Central Lancashire, Sunderland, Durham, De Montfort, East Anglia, Greenwich, Hertfordshire, Huddersfield, Keele, Kingston, Lincoln, Liverpool John Moores, University College London, King's College London, Portsmouth, Reading, Sussex, Manchester, Nottingham, Wolverhampton, Robert Gordon, Strathclyde, Cardiff, Queen's University Belfast, Ulster (Coleraine).
- Healthwatch England
- Community Pharmacy Futures
- Pharmaceutical Services Negotiating Committee
- Centre for Pharmacy Postgraduate Education
- Royal Pharmaceutical Society
- Community Pharmacy Northern Ireland
- Community Pharmacy Scotland
- Community Pharmacy Wales
- Public Health England
- Department of Health
- Welsh Assembly
- Scottish Government
- NHS England

The following limits will be applied to the search:

- Date limit of 1990 to 2016
- English language

A study filter will not be applied.

Citation searching of included studies will be undertaken.



Results will be saved to an EndNote database and de-duplicated. Results will be provided to the Public Health team as RIS files, suitable for import into EPPI Reviewer

A record will be kept of number of records found from each database and of the strategy used in each database. A record will be kept of total number of duplicates found and of total results provided to the Public Health team.

***Methods for assessing bias at outcome or study level***

Standard study checklists will be used to critically appraise individual studies. For details please see section 6.2 of Developing NICE guidelines: the manual

Where appropriate, the risk of bias across all available evidence will be evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group <http://www.gradeworkinggroup.org/>.

## **Appendix B – Literature search strategies**

[See separate appendix B document.](#)

## **Appendix C – Effectiveness and acceptability included evidence**

1. Evans SW, John DN, Bloor MJ, Luscombe DK. Use of non-prescription advice offered to the public by community pharmacists. *International Journal of Pharmacy Practice*. 1997 Mar 1;5(1):16-25.
2. Michie L, Cameron S, Glasier A et al. (2014) Pharmacy based interventions for initiating effective contraception following the use of emergency contraception: a pilot study. *Contraception*, vol 90 (4), p447-453.
3. Michie J, Cameron ST, Glasier A et al (2016) Provision of contraception after emergency contraception from the pharmacy: evaluating the acceptability of pharmacy for providing sexual and reproductive health services, 135: 97-103
4. Perraudin C, Fleury B, Pelletier-Fleury N. (2015) Effectiveness of intervention led by a community pharmacists for improving recognition of sleep apnea in primary care- a cohort study, 24: 167-173
5. Sriram Deepa, McManus Alexandra, Emmerton Lynne M, Parsons Richard W, and Jiwa Moyez (2016) A model for assessment and referral of clients with bowel symptoms in community pharmacies. *Current medical research and opinion* 32(4), 661-7.

## Appendix Di – Effectiveness evidence tables

Study details	Population	Intervention and comparator	Methods and analysis	Results																										
<p><b>Reference</b> Evans SW, John DN, Bloor MJ, Luscombe DK. Use of non-prescription advice offered to the public by community pharmacists. International Journal of Pharmacy Practice. 1997 Mar 1;5(1):16-25.</p> <p><b>Quality score</b> -</p> <p><b>Study type</b> Observational - cohort study</p> <p><b>Location and setting</b> High street and village pharmacies situated in south-east Wales</p> <p><b>Aims</b> To establish whether members of the public utilise the specific</p>	<p><b>Health area</b> Any</p> <p>Number of participants N=98 participants</p> <p>215 fulfilled entry criteria; 34 subsequently excluded as ineligible; 98 were successfully interviewed</p> <p>4 pharmacies</p> <p><b>Participant characteristics</b></p> <table border="1"> <thead> <tr> <th>Age</th> <th></th> </tr> </thead> <tbody> <tr> <td>18-40</td> <td>40</td> </tr> <tr> <td>41-60</td> <td>32</td> </tr> <tr> <td>61+</td> <td>24</td> </tr> <tr> <th>Gender</th> <th></th> </tr> <tr> <td>Female</td> <td>79</td> </tr> <tr> <td>Male</td> <td>19</td> </tr> </tbody> </table> <p>Participants presented with a wide range of conditions, including: eye, skin, respiratory, pain, gastrointestinal tract, oral and other miscellaneous conditions</p> <p><b>Inclusion criteria</b> Individuals who had requested advice or presented at the pharmacy describing symptoms</p> <p>An individual who was advised by a pharmacist regarding a</p>	Age		18-40	40	41-60	32	61+	24	Gender		Female	79	Male	19	<p><b>Direct suggestion of GP appointment:</b> Where a client is advised to seek advice from elsewhere regardless of the outcome of the presenting symptoms</p> <p><b>Conditional suggestion of GP appointment:</b> Where a client is advised to seek advice only if another criterion is met, for example, if the presenting symptom worsens or does not improve</p>	<p><b>Recruitment:</b> A random selection of 6 independent community pharmacies in south-east Wales were sent an invitation to participate</p> <p>Individuals were approached as they were leaving the pharmacy if they fulfilled the inclusion criteria and asked to participate.</p> <p><b>Methods:</b> Telephone interviews were undertaken with clients 4-8 days after their pharmacy visit using a structure instrument which mainly consisted of closed questions.</p> <p>Questions were asked to determine client adherence with any advice on making an appointment with a GPI.</p> <p>All recorded pharmacist-client interactions which fulfilled the entry criteria were timed and transcribed verbatim, as were the researcher-client interviews.</p> <p><b>Analysis:</b> 4 statistical tests were used, namely the Kruskal-Wallis test, the Mann-Whitney U test, the Chi-squared test and Pearson's product moment correlation.</p>	<p><b>Primary outcomes:</b> <u>Uptake of appointment</u></p> <p>All suggestions for appointments made by the pharmacists were to with a GP. Uptake of appointment means here to have made a visit to the GP between the time of appointment being suggested by the pharmacist and the time of interview (4-8 days later).</p> <table border="1"> <thead> <tr> <th></th> <th>Number of people</th> <th>Number of appointments attended</th> <th>Uptake %</th> </tr> </thead> <tbody> <tr> <td>Direct suggestion</td> <td>10</td> <td>7</td> <td>70.0</td> </tr> <tr> <td>Conditional suggestion</td> <td>30</td> <td>4</td> <td>13.3</td> </tr> </tbody> </table>		Number of people	Number of appointments attended	Uptake %	Direct suggestion	10	7	70.0	Conditional suggestion	30	4	13.3
Age																														
18-40	40																													
41-60	32																													
61+	24																													
Gender																														
Female	79																													
Male	19																													
	Number of people	Number of appointments attended	Uptake %																											
Direct suggestion	10	7	70.0																											
Conditional suggestion	30	4	13.3																											

<p>advice offered by community pharmacists and adhere with advice offered on referrals</p> <p><b>Length of follow up</b> 4-8 days</p> <p><b>Source of funding</b> Welsh Pharmacy Practice Research Enterprise Scheme</p>	<p>minor ailment and/or an over the counter medicine</p> <p>An individual who was offered advice intended for their own use or for someone under their care</p> <p><b>Exclusion criteria</b> Professional carers, seeking advice for an individual they care for.</p> <p>Those who reported not having a telephone</p> <p>Those not available for interview</p>		<p>Values for these tests were considered statistically significant if the probability was <math>\leq 0.005</math></p>	
<p><b>Limitations identified by authors</b> As recordings of the pharmacist-client interaction were made with the pharmacist knowledge, the possibility of the Hawthorne effect cannot be discounted 16 of those invited to participate in the study were found not to have a telephone and so a possible sample bias could have been introduced</p> <p><b>Limitations identified by review team</b> It is unknown whether the participants who were given conditional appointment later fulfilled the conditions set by pharmacists to warrant a GP visit. This is an observational study and thus the intervention could not be properly controlled or regulated across sites. The follow up time is short and inconsistent (4-8 days), and no data is collected on intent to seek appointment. It is possible that individuals who received 'conditional appointment' were more likely to have a longer delay between suggestion of appointment and uptake. Participant selection was not randomised. Baseline characteristics of the groups were not compared. Outcomes were self-reported. 54% of participants were successfully followed up but it is not clear how many eligible community pharmacy users were recruited into the study. The consistency of the intervention across different sites or different days was not measured.</p> <p><b>Other comments</b> Medicine related outcomes are also reported in this study, but have been excluded from this review</p>				

Study details	Population	Intervention and comparator	Methods and analysis	Results																																								
<p><b>Reference</b>                      Michie L, Cameron S, Glasier A et al. (2014) Pharmacy based interventions for initiating effective contraception following the use of emergency contraception: a pilot study. Contraception, vol 90 (4), p447-453</p> <p><b>Quality score</b>                      +</p> <p><b>Study type</b>                      Randomised controlled trial</p> <p><b>Location and setting</b>                      Community pharmacies in Edinburgh, UK</p> <p><b>Aims</b>                      To determine the feasibility of a larger study, investigating whether either</p>	<p><b>Health area</b>                      Sexual health</p> <p><b>Number of participants</b>                      n=168 pharmacy users                      11 pharmacists from 11 pharmacies</p> <p><b>Participant characteristics</b>                      Mean age of all participants= 23 years (SD 5.2)</p> <p><i>Mean age of participants completing the telephone interview:</i>                      POP group: 22 years (SD 5.2), range 18 to 44</p> <p>Rapid access group: 25 years (SD 5.6), range 18 to 40</p> <p>Standard care=23 years (SD 4.5), range 18 to 36</p> <p>Contraception at time of recruitment:</p> <table border="1"> <thead> <tr> <th></th> <th>POP group</th> <th>Rapid access group</th> <th>Control</th> </tr> </thead> <tbody> <tr> <td>None</td> <td>13 (33%)</td> <td>8 (28%)</td> <td>12 (34%)</td> </tr> <tr> <td>Condoms</td> <td>26 (67%)</td> <td>17 (61%)</td> <td>19 (54%)</td> </tr> <tr> <td>Other</td> <td>0</td> <td>3 (11%)</td> <td>4 (12%)</td> </tr> </tbody> </table> <p>Statistical significance and p values for differences between groups at baseline not reported.</p> <p><b>Inclusion criteria</b>                      Pharmacy users:</p> <ul style="list-style-type: none"> <li>Women aged 16 or over</li> </ul>		POP group	Rapid access group	Control	None	13 (33%)	8 (28%)	12 (34%)	Condoms	26 (67%)	17 (61%)	19 (54%)	Other	0	3 (11%)	4 (12%)	<p><b>Intervention (n=58)</b>                      'Rapid access'. Participants were told to take their empty packet of emergency contraception to the local specialist family planning centre to discuss contraception, as soon as possible. Women were seen on the day they presented without having to book an appointment, and were offered all methods of contraception to start immediately. Pharmacists provided written information about the location and opening hours of the family planning clinic.</p> <p><b>Progesterone Only Pill (POP) group (n=56)</b></p>	<p>Cluster randomisation by pharmacy. Restricted randomisation used to ensure balance between study arms in respect to emergency contraception dispensing figures and the deprivation category.</p> <p>4 pharmacies were randomised to intervention and 3 to standard care. Four months into the study, a pharmacist in the standard care arm retired, so the pharmacy was replaced with another pharmacy.</p> <p><b>Recruitment:</b>                      April 2012 to December 2012</p> <p><b>Analysis:</b>                      Some women using hormonal contraception were accidentally recruited and so were excluded from the analysis (n=3 in intervention and 4 in standard care arm).</p> <p>Power calculation was not performed. Aimed to recruit 180 women from 10 to 12 pharmacies.</p> <p>Proportions in each cluster using effective contraception compared using two-sample t tests.</p>	<table border="1"> <thead> <tr> <th></th> <th>POP group</th> <th>Rapid Access group</th> <th>Standard care</th> </tr> </thead> <tbody> <tr> <td>Allocated</td> <td>56</td> <td>58</td> <td>54</td> </tr> <tr> <td>Lost to follow up</td> <td>17</td> <td>30</td> <td>19</td> </tr> <tr> <td>Analysed</td> <td>39</td> <td>28</td> <td>35</td> </tr> </tbody> </table> <p>In POP group 35/39 (90%) reported using pills provided. Two women didn't use pills because they were not currently sexually active, one did not get around to using them and one was concerned about side effects. Most women 26/35 (74%) who took the pill reported completing the packet; 5 used between 7 and 14 pills; 3 delayed starting and had not finished the pack at time of interview.</p> <p>In rapid access intervention group, 9/28 (32%) women attended the family planning clinic – 3 on the day they obtained emergency contraception and the rest between 2 days and 1 month later. Most common reason for not attending for rapid access contraception was 'pressure of time' (n=10, 53%). Additional reasons included 'prefer to see GP' (n=1), 'still considering contraceptive options' (n=1), 'family planning clinic too far away' (n=1), 'forgot' (n=1), 'not sexually active' (n=2) and 2 women stated that 'the option was not clearly explained to them'.</p> <p>8 (23%) women in the standard care arm said they received information from the pharmacists about the range of methods of contraception available or where they could obtain contraception. 8 (23%) said they had not received any information on methods available and 6 (17%) said they had not received any information about where they could get contraception.</p> <p>Method of contraception use at 6 to 8 weeks:</p> <table border="1"> <thead> <tr> <th></th> <th>POP group</th> <th>Rapid Access group</th> <th>Standard Care</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		POP group	Rapid Access group	Standard care	Allocated	56	58	54	Lost to follow up	17	30	19	Analysed	39	28	35		POP group	Rapid Access group	Standard Care				
	POP group	Rapid access group	Control																																									
None	13 (33%)	8 (28%)	12 (34%)																																									
Condoms	26 (67%)	17 (61%)	19 (54%)																																									
Other	0	3 (11%)	4 (12%)																																									
	POP group	Rapid Access group	Standard care																																									
Allocated	56	58	54																																									
Lost to follow up	17	30	19																																									
Analysed	39	28	35																																									
	POP group	Rapid Access group	Standard Care																																									

<p>intervention resulted in an increased proportion of women self-reporting use of effective ongoing contraception at 6 to 8 weeks after emergency contraception use, compared to standard care.</p> <p><b>Length of follow up</b> 6 to 8 weeks</p> <p><b>Source of funding</b> See 'other comments' below.</p>	<ul style="list-style-type: none"> <li>Presenting for emergency contraception who had been using either no contraception or barrier method</li> <li>Women eligible for emergency contraception according to patient group directive criteria with no medical contraindications (e.g. unexplained vaginal bleeding, pregnancy, severe hepatic dysfunction, severe malabsorption syndrome, previous unprotected sexual intercourse in the same menstrual cycle or unprotected sex over 72 hours earlier)</li> <li>UK resident</li> <li>Not requiring language interpreting services</li> </ul> <p>Pharmacists who had previous experience in research or dispensed 10 or more courses of emergency contraception a month.</p> <p><b>Exclusion criteria</b> Pharmacy users: Already using hormonal contraception.</p>	<p>Packet of 35 POP provided by pharmacist using locally approved patient group directive (PGD) at no cost to women as a bridging method of contraception giving them 1 month to attend their usual healthcare provider for ongoing contraception. PGD allows pharmacist to dispense certain approved medications without a prescription.</p> <p><b>Comparator (n=54)</b> 'Standard care'. Pharmacists dispensed emergency contraception and could provide usual verbal and/or written information on contraception. All pharmacies have leaflets detailing location and services of local</p>	<p>78% of recruited participants were contactable by phone 6 to 8 weeks later and 102 (61% of all participants) completed the interview. There was no significant difference in age between women contacted and those not contacted (no other data were available for those not contacted). Lost to follow up: decline interview (n=11 in intervention group, n=10 in standard care), no answer to phone all (n=5 in intervention group, n=4 in standard care), no/wrong phone number (n=11 intervention group, n=5 in standard care), no consent form (n=1 in intervention) or not in country (n=1 in intervention).</p> <p>Participants using the same form of contraception at follow up at baseline were excluded from the analysis – 3 people in intervention and 4 people in standard care.</p>	<table border="1" data-bbox="1400 268 2060 494"> <tr> <td rowspan="2">'Effective' contraception</td> <td>All effective methods</td> <td>22 (56%)</td> <td>13 (52%) **</td> <td>5 (16%)</td> </tr> <tr> <td>Long-acting reversible contraception</td> <td>3 (8%) **</td> <td>5 (20%) **</td> <td>0</td> </tr> <tr> <td colspan="2">No/barrier method</td> <td>17 (44%)</td> <td>12 (48%)</td> <td>26 (84%)</td> </tr> </table> <p>** p&lt;0.01 vs. standard care</p> <p>Relative risk of using effective contraception at 6 to 8 weeks RR= 2.57 (95% CI 1.55 to 4.27), p=0.006 Rapid referral group RR= 3.13 (95% CI 1.90 to 5.13),</p> <p>Relative risk of using long-acting reversible contraception 6 to 8 weeks after emergency contraception was 20% in intervention compared to 0% in standard care group (p=0.004).</p> <p>If assume baseline observation carried forward, there would still be a significant increase in the use of an effective method in intervention vs. standard care (22% vs. 9%, p=0.043).</p>	'Effective' contraception	All effective methods	22 (56%)	13 (52%) **	5 (16%)	Long-acting reversible contraception	3 (8%) **	5 (20%) **	0	No/barrier method		17 (44%)	12 (48%)	26 (84%)
'Effective' contraception	All effective methods	22 (56%)	13 (52%) **	5 (16%)														
	Long-acting reversible contraception	3 (8%) **	5 (20%) **	0														
No/barrier method		17 (44%)	12 (48%)	26 (84%)														

		family planning clinics.		
<p><b>Limitations identified by authors</b>                  Loss to follow up was high, including lack of willingness to be interviewed at follow up. Contraception use at 6 to 8 weeks was self-reported. Lacking robust data on women who were not recruited to the study – cannot rule out selective recruitment. Intended sample size was not recruited and telephone interviews only completed in 60% of participants.</p> <p><b>Limitations identified by review team</b>                  It is unclear how the allocation sequence was generated. It is unclear if the allocation was concealed. The baseline outcome measurements and characteristics appear to be similar between groups, however, statistical significance and p values are not reported. It is unclear whether outcomes were assessed blindly.</p> <p><b>Other comments</b>                  This study also included 'intervention 1' which was a 30 day supply of hormonal contraception, however, this is not a relevant intervention for this review question and so is not presented here. This was a pilot study. Pharmacists were compensated £10 per participant recruited. The Edinburgh and Lothians Health Foundation provided funding for this study. In addition, a research grant was provided by HRA Pharma which enabled LM to be funded as a clinical research fellow at The University of Edinburgh. Both STC and AG currently and in the past have received research support from and undertaken consultancies for pharmaceutical companies working to develop emergency contraception.</p>				

Study details	Population	Intervention and comparator	Methods and analysis	Results																																												
<p><b>Reference</b> Perraudin 2015 Quality score +</p> <p><b>Study type</b> Cohort</p> <p><b>Location and setting</b> France, Community pharmacies</p> <p><b>Aims</b> To assess the feasibility and effectiveness of community pharmacist led intervention for improving recognition of Obstructive Sleep Apnea Syndrome (OSAS) in primary care and increase the use of diagnostic tests.</p> <p><b>Length of follow up</b> 6 months</p> <p>Source of funding</p>	<p><b>Health area</b> Obstructive Sleep Apnea Syndrome (OSAS)</p> <p><b>Number of participants</b> 88 pharmacy clients (seen by 31 pharmacists)</p> <p>Participant characteristics</p> <table border="1"> <thead> <tr> <th></th> <th>Intervention group (N=88)</th> <th>Control Group (n=694)</th> </tr> </thead> <tbody> <tr> <td>Women</td> <td>28 (32%)</td> <td>278 (40%)</td> </tr> <tr> <td>Age (Mean, sd)</td> <td>62.2 (12.6)</td> <td>62.7 (11.7)</td> </tr> <tr> <td>BMI (Mean, sd)</td> <td>30.3 (4.6)</td> <td>30.6 (4.6)</td> </tr> <tr> <td>Education</td> <td></td> <td></td> </tr> <tr> <td>Primary</td> <td>28.4%</td> <td>45.1%**</td> </tr> <tr> <td>Secondary &amp; higher ed</td> <td>55.7%</td> <td>41.1%</td> </tr> <tr> <td>&gt;High ed</td> <td>15.9%</td> <td>13.8%</td> </tr> <tr> <td>Retired</td> <td>61.4%</td> <td>57.8%</td> </tr> <tr> <td>Epworth score</td> <td></td> <td></td> </tr> <tr> <td>&lt;10</td> <td>63.6%</td> <td>44.7%</td> </tr> <tr> <td>&gt;=10</td> <td>25.0%</td> <td>21.9%</td> </tr> </tbody> </table> <p>** - p&lt;0.05</p> <p><u>Flow of participants in INTERVENTION GROUP (n=88)</u> In intervention group 70/88 (79.5%) consulted their GP -61/70 (87%) gave letter to GP (9 did not give letter to GP)</p>		Intervention group (N=88)	Control Group (n=694)	Women	28 (32%)	278 (40%)	Age (Mean, sd)	62.2 (12.6)	62.7 (11.7)	BMI (Mean, sd)	30.3 (4.6)	30.6 (4.6)	Education			Primary	28.4%	45.1%**	Secondary & higher ed	55.7%	41.1%	>High ed	15.9%	13.8%	Retired	61.4%	57.8%	Epworth score			<10	63.6%	44.7%	>=10	25.0%	21.9%	<p><b>Intervention</b> Patients provided with OSAS detailed brochure with comments from community pharmacists to inform about consequences if OSAS left untreated. At end of encounter, given the estimated pretest risk of OSAS, pharmacists advised participants to consult their GP. A letter to the doctor, signed by the pharmacist given to patients, explaining that the patient was involved in a research study. All data collected were attached to letter and stressed need for GP-pharmacists collaboration and urged GP to continue investigations for these patients at risk of OSAS.</p> <p>Patients monitored for 6 months. Pharmacists were to call participants at 1,3 &amp; 6 months.</p> <p><b>Comparator</b> No intervention. To test whether these individuals underwent diagnostic testing they were asked "Have you ever had a sleep recording performed at</p>	<p><b>Recruitment:</b> Pharmacists recruited on voluntary basis. Each pharmacist asked to include at least 4 patients each.</p> <p><b>INTERVENTION GROUP</b> -Made aware of OSAS screening campaign through posters displayed on window. During visits by regular overweight patients coming to renew their anti-hypertensive prescription the pharmacist would ask if they snored. Eligible patients included consecutively. Anthropometric data, SES and medication history data collected.</p> <p><b>CONTROL GROUP</b> -Patients selected from the Health Social Protection Survey (ESPS) which is a panel survey conducted by the French Institute for Research and Information in health Economics every two year. Aim of ESPS is to provide a detailed picture of state of health, health-care utilization and level of health insurance. In 2008 questions concerning sleep disorders were included for people aged 16 years or older. All respondents who met the inclusion/ exclusion were included in the control group.</p>	<p><b>Primary outcomes:</b> <u>Underwent diagnostic test for OSAS (N=782)</u></p> <table border="1"> <thead> <tr> <th></th> <th>Intervention Group (N=88)</th> <th>Control Group (N=694)</th> <th>Statistical test</th> </tr> </thead> <tbody> <tr> <td>N (%)</td> <td>20 (22.7%)</td> <td>79 (11.4%)</td> <td>X<sup>2</sup> test P=0.003</td> </tr> </tbody> </table> <p>Adjusted OR=2.24 (95%CI 1.25-4.01) for those in the intervention group to undergo OSAS diagnostic test relative to those in the control group.</p> <p><b>Secondary outcomes:</b> none</p>		Intervention Group (N=88)	Control Group (N=694)	Statistical test	N (%)	20 (22.7%)	79 (11.4%)	X <sup>2</sup> test P=0.003
	Intervention group (N=88)	Control Group (n=694)																																														
Women	28 (32%)	278 (40%)																																														
Age (Mean, sd)	62.2 (12.6)	62.7 (11.7)																																														
BMI (Mean, sd)	30.3 (4.6)	30.6 (4.6)																																														
Education																																																
Primary	28.4%	45.1%**																																														
Secondary & higher ed	55.7%	41.1%																																														
>High ed	15.9%	13.8%																																														
Retired	61.4%	57.8%																																														
Epworth score																																																
<10	63.6%	44.7%																																														
>=10	25.0%	21.9%																																														
	Intervention Group (N=88)	Control Group (N=694)	Statistical test																																													
N (%)	20 (22.7%)	79 (11.4%)	X <sup>2</sup> test P=0.003																																													



None reported	<p>-40/70 (57%) were referred to sleep specialist (21 not referred to sleep specialist)                  -20/40 (50%) performed diagnostic test                  -17/20 (85%) had a positive diagnosis (3 had a negative diagnosis)</p> <p>Inclusion criteria                  Pharmacists: No a priori criteria  <u>Pharmacy clients:</u>                  -Taking one or more antihypertensive drugs, being overweight (BMI &gt;=25) and snoring almost every night. Pretest probability of having OSAS estimated at 82% in this population                  Exclusion criteria                  -Patients under OSAS treatment, not having a referent GP, having a long-term illness and not having the capacity to sign an informed consent</p>	<i>the hospital or at home?"</i>	<p><b>Analysis:</b>                  t-test and chi-square tests to compare continuous and categorical variables. Logistic regression adjusted to gender, age, BMI, education, Employment status and Epworth score to analyse the independent effect of intervention on the primary outcome of interest.</p>	
<p><b>Limitations identified by authors</b>                  Pharmacists reported difficulties in recruiting patients due to lack of time and having to recruit patients directly at the counter with two-thirds indicating there were no private consultation areas. Way in which patients were recruited to intervention group could lead to selection bias as researchers were not sure recruitment was always consecutive as instructed. No information available on the individuals who declined to participate in the intervention arm. Follow-up period lasted for only six months which could have lead to an underestimation of the proportion of diagnostic test. 20 patients referred by their GP to sleep specialist but did not undergo testing. Perhaps if research period was longer they may have had the chance to go for testing.</p> <p><b>Limitations identified by review team</b>                  Possible that individuals selected for the intervention may have also been respondents to the national survey from which the control population was drawn.</p>				

Study details	Population	Intervention and comparator	Methods and analysis	Results						
<p><b>Reference</b>                      Sriram Deepa, McManus Alexandra, Emmerton Lynne M, Parsons Richard W, and</p>	<p><b>Health area</b>                      Cancer awareness</p> <p><b>Number of participants</b></p> <table border="1" data-bbox="398 1345 824 1401"> <tr> <td></td> <td><b>Usual practice</b></td> <td><b>Intervention</b></td> </tr> </table>		<b>Usual practice</b>	<b>Intervention</b>	<p><b>Intervention</b>                      Jodi Lee Test (JLT) guide was used in decision-making during the pharmacist's consultation with</p>	<p><b>Recruitment:</b>                      A convenience sample of 21 pharmacies was recruited</p> <p>Pharmacy staff recruited clients seeking advice for bowel symptoms or seeking medicines</p>	<p><b>Primary outcomes:</b>  <u>Uptake of referral:</u>                      Attendance rate for general practitioner consultation was higher during the intervention phase:</p> <table border="1" data-bbox="1473 1369 2060 1409"> <tr> <td></td> <td><b>Usual practice</b></td> <td><b>Intervention</b></td> </tr> </table>		<b>Usual practice</b>	<b>Intervention</b>
	<b>Usual practice</b>	<b>Intervention</b>								
	<b>Usual practice</b>	<b>Intervention</b>								

<p>Jiwa Moyez (2016) A model for assessment and referral of clients with bowel symptoms in community pharmacies. Current medical research and opinion 32(4), 661-7</p> <p><b>Quality score</b> -</p> <p><b>Study type</b> Uncontrolled before and after</p> <p><b>Location and setting</b> Perth metropolitan area and regional towns covering a range of socioeconomic areas.</p> <p><b>Aims</b> To examine the feasibility and effectiveness of the use of the Jodi Lee Test (JLT) as a guide to pharmacy staff to identify clients with bowel symptoms warranting general</p>	<table border="1"> <tr> <td><b>Pharmacy no.</b></td> <td>21</td> <td>19</td> </tr> <tr> <td><b>Recruited</b></td> <td>84</td> <td>80</td> </tr> <tr> <td><b>Referred</b></td> <td>17 (20%)</td> <td>30 (38%)</td> </tr> <tr> <td><b>No. referred followed up</b></td> <td>14</td> <td>27</td> </tr> </table>	<b>Pharmacy no.</b>	21	19	<b>Recruited</b>	84	80	<b>Referred</b>	17 (20%)	30 (38%)	<b>No. referred followed up</b>	14	27	<p>clients. The JLT is a paper-based questionnaire comprising 8 questions, which was self-completed by clients in a private or semi-private area in the pharmacy, if available, with assistance of the staff member, if required. On reviewing the completed JLT, the attending pharmacy assistant decided whether or not to refer the client to the pharmacist; likewise, the pharmacist applied his/her clinical judgement regarding referral to the client's general practitioner. If referred, the pharmacist completed details on a standard referral letter, issued to the client with the completed JLT.</p> <p><b>Comparator</b> <u>Usual practice:</u></p>	<p>normally used to treat diarrhoea, constipation or haemorrhoids during both usual care and intervention phases of the study, over a 12 week period during usual care and 20 weeks for intervention phases.</p> <p><b>Methods:</b> Follow up of the recruited clients during usual practice took place 4 weeks following their pharmacy visit. Clients were contacted by telephone to determine if their referrals were acted upon. Participants not contactable for follow-up after 3 attempts were deemed lost to follow-up.</p> <p>For the intervention group, recruitment started 4 weeks after the completion of the usual practice phase. Clients who were referred for consultation with a general practitioner were contacted by the researcher 4 weeks after their pharmacy visit to determine if they had visited the GP.</p> <p>Intervention pharmacies were those that completed the usual practice phase.</p> <p><b>Analysis:</b> The effectiveness of the JLT intervention was determined by comparison of general practitioner attendance rates for clients referred to the general</p>	<table border="1"> <tr> <td><b>Number referred</b></td> <td>14</td> <td>27</td> </tr> <tr> <td><b>Uptake number</b></td> <td>1</td> <td>12</td> </tr> <tr> <td><b>Uptake rate</b></td> <td>6%*</td> <td>40%*</td> </tr> </table>	<b>Number referred</b>	14	27	<b>Uptake number</b>	1	12	<b>Uptake rate</b>	6%*	40%*
	<b>Pharmacy no.</b>	21	19																						
<b>Recruited</b>	84	80																							
<b>Referred</b>	17 (20%)	30 (38%)																							
<b>No. referred followed up</b>	14	27																							
<b>Number referred</b>	14	27																							
<b>Uptake number</b>	1	12																							
<b>Uptake rate</b>	6%*	40%*																							
<p><b>Participant characteristics</b> <u>Pharmacist characteristics:</u> 122 pharmacy assistants 62 pharmacists 7 pre-registered pharmacists</p> <table border="1"> <thead> <tr> <th></th> <th>Usual practice</th> <th>Intervention</th> </tr> </thead> <tbody> <tr> <td><b>Male</b></td> <td>24 (29%)</td> <td>26 (33%)</td> </tr> <tr> <td><b>Female</b></td> <td>60 (71%)</td> <td>54 (68%)</td> </tr> </tbody> </table> <p><b>Inclusion criteria</b> 18+ years Able to give written informed consent, including contact by the researcher for follow-up</p> <p><b>Exclusion criteria</b> None specified</p>		Usual practice	Intervention	<b>Male</b>	24 (29%)	26 (33%)	<b>Female</b>	60 (71%)	54 (68%)	<p>*Reported as 7% and 44% in the study paper, but calculated as 6% and 40% by NICE technical team.</p> <p>RR 6.22 (95% CI 0.90 to 43.09) for uptake for usual practice vs. intervention [calculated by NICE technical team]</p>															
	Usual practice	Intervention																							
<b>Male</b>	24 (29%)	26 (33%)																							
<b>Female</b>	60 (71%)	54 (68%)																							

<p>practitioner assessment.</p> <p><b>Length of follow up</b> 4 weeks</p> <p><b>Source of funding</b> Supported by a Jodi Lee Foundation PhD scholarship</p>		<p>Referrals for further investigation if required. The participants were advised of the need for a medical consultation and given a referral letter to take to the general practitioner.</p>	<p>practitioner following use of the JLT compared to usual practice. Differences in referral rates and the general practitioner consultations were assessed using the Chi-square and Fisher's exact test. A p-value &lt;0.005 was interpreted as indicating a statistically significant association.</p>	
<p><b>Limitations identified by authors</b> The study protocol was not consistently applied in some pharmacies. Adherence to the study protocol by individual staff was not able to be controlled.</p> <p><b>Limitations identified by review team</b> Low participant numbers</p> <p><b>Other comments</b> None</p>				

## Appendix Dii – Acceptability evidence tables

Study details	Research Parameters	Inclusion/ Exclusion criteria	Population	Results
<p><b>Author name and year</b> Michie, 2016</p> <p><b>Quality score</b> +</p> <p><b>Study type</b> Qualitative</p> <p><b>Aim of the study</b> Pilot study to identify barriers and facilitators of providing pharmacy based interventions to increase uptake of effective contraception after emergency contraception (EC).</p> <p><b>Location and setting</b> Edinburgh, UK, Community pharmacies</p>	<p><b>Intervention</b> Cluster RCT where pharmacies provided: A) One month supply of packet of progesterone only pills (POP) with option to arrange ongoing contraception B) Invite to present empty EC pack to family planning clinic for contraceptive advice (rapid access) C) Standard care</p> <p><b>Sample frame</b> 49 women asked to participate, 26 (53%) agreed, purposive sample of 12 interviewed.</p> <p><b>Data collection</b> Face to face semi-structured interviews lasting about 1 hour and conducted between Aug-Nov 2012. Used topic guide to facilitate the generation of data that could be and allow women to raise issues that were important to them and inform future development of research and</p>	<p><b>Inclusion</b></p> <ul style="list-style-type: none"> <li>• Women aged 16 or over</li> <li>• Presenting for emergency contraception who had been using either no contraception or barrier method</li> <li>• Women eligible for emergency contraception according to patient group directive criteria with no medical contraindications (e.g. unexplained vaginal bleeding, pregnancy, severe hepatic dysfunction, severe malabsorption syndrome, previous unprotected sexual intercourse in the same menstrual cycle or unprotected sex over 72 hours earlier)</li> <li>• UK resident</li> <li>• Not requiring language interpreting services</li> </ul>	<p><b>Health Area</b> Sexual Health</p> <p><b>12 women</b></p> <ul style="list-style-type: none"> <li>- Mean age 26 (SD 5.5)</li> <li>- Depcat score <ul style="list-style-type: none"> <li>o Affluent: 1 (8%)</li> <li>o Moderate: 10 (83%)</li> <li>o Deprived: 1 (8%)</li> </ul> </li> <li>- Previous birth: 0</li> <li>- Previous abortion: 1 (8%)</li> </ul>	<p><u>Experience/ Acceptability</u></p> <p>Women cited difficulties with accessing GP appointments for EC and thinking that it would not be seen as a priority for your GP to discuss</p> <p><i>“I don’t want to trouble my GP for minor health concerns so I prefer to self-medicate or go to the pharmacy across from where I live where they operate a drop-in system to suits me better“- standard care group“</i></p> <p>Provision of month supply of POP</p> <p>Mixed views articulated. Some women thought one month supply was sufficient to make a follow-up appointment to access further supply or discuss other methods some women felt one month supply was a “waste of time“ or put women off using hormonal methods</p> <p><i>“I think it will be useful for other women... but for myself and others it will take a while for the pill to settle, so a month supply may not be worth it as it may not give a good indication of side effects.. “- (standard care grp)</i></p> <p>Some felt being offered POP at pharmacy was a good alternative to accessing it only at the GP or the Family Planning Clinic</p> <p><i>“It is good to do this because some people can be hesitant going on it and asking about it from their GP. So if they are offered they can try it. It’s easier to ask the GP for more rather than to start on it. A month supply should be enough to make an appointment with their GP“- (POP group)</i></p>

Study details	Research Parameters	Inclusion/ Exclusion criteria	Population	Results
<p><b>Source of funding</b></p> <p>Edinburgh &amp; Lothians Health Foundation, HRA Pharma funded lead author for clinical fellowship</p>	<p>clinical implementation of interventions. Interviews audio-recorded and transcribed verbatim. Research log used by research team to record operational issues.</p> <p><b>Method of analysis</b></p> <p>Cross-sectional indexing and thematic analysis.</p>	<p><b>Exclusion</b></p> <ul style="list-style-type: none"> <li>- Women already on hormonal contraception</li> </ul>		<p>Some had reservations about starting a new hormonal method at the time of presenting for EC. Some women questioned if it was the role of the pharmacist to undertake contraception consultations</p> <p><i>"I think for women like me who have never tried hormones before it is not a good idea. I want to speak to someone about different options and health implications of hormones before I take them. My GP was surprised when I mentioned that I was given the pills at the pharmacy, it was not a good method for me" – (POP group)</i></p> <p>All 4 women in POP arm said they were provided with info by pharmacists and given opportunity to ask questions about POP but 3 felt they went away having questions about POP which they did not feel able to ask at the time.</p> <p>PROVISION OF RAPID ACCESS (RA) APPOINTMENT</p> <p>All women liked the idea of being provided with an RA appointment as it enabled quicker access to consultations and potentially more specialist support that can help match women to suitable and effective methods of contraception</p> <p><i>"Getting EC can kick start your brain to think about wanting to get on the pill or something...an appointment to see someone quickly to discuss more will be really helpful" (standard care group)</i></p> <p><i>"...having an appointment to see someone quickly to discuss more will be really helpful" (Standard care group)</i></p> <p>Time between presenting for EC and having appointment would allow time to reflect on her experience and seek appropriated clinical and emotional support</p>

Study details	Research Parameters	Inclusion/ Exclusion criteria	Population	Results
<p><b>Notes</b></p> <p><b>Limitations identified by author</b></p> <p>Difficult to conduct high quality research in this setting. Was difficult to retain pharmacists during the study and slow recruitment of women into the study. This is a small study with a small sample of women from a single urban site so results may not be applicable to rural pharmacies.</p> <p><b>Limitations identified by review team</b></p>				

## Appendix E – Forest plots

No forest plots were created for this review.

## Appendix F – GRADE tables

### GRADE profile 1: Uptake of services

Quality assessment								No. of participants	Effect	Quality of evidence for outcome	Importance of outcome
No. of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations					
Uptake of GP appointment											
Suggestion of GP appointment for any health condition based on presenting symptoms vs. suggestion based on symptoms not improving or worsening											
1 <sup>1</sup>	Observational cohort study	Very serious <sup>a</sup>	Not applicable	Serious <sup>b</sup>	Serious <sup>c</sup>	No	40	RR 5.25 (95% CI 1.93 to 14.25) favouring presenting symptoms	Very low	Critical	
Standard referral letter based on results of Jodi Lee test for bowel cancer symptoms vs. standard referral letter based on pharmacist opinion of bowel cancer symptoms											
1 <sup>2</sup>	Before and after study	Very serious <sup>d</sup>	Not applicable	No serious	Very serious <sup>e</sup>	No	41	RR 6.22 (95% CI 0.90 to 43.09)	Very low	Critical	
Uptake of appointment with family planning clinic or other contraception provider											
Empty box of emergency contraception to take to family planning clinic vs. verbal and written advice on methods of contraception, including locations of family planning clinics											
1 <sup>3</sup>	Randomised controlled trial	Serious <sup>f</sup>	Not applicable	Serious <sup>g</sup>	Serious <sup>c</sup>	No	61	RR 3.72 <sup>h</sup> (95% CI 1.58 to 8.74) favouring empty box	Very low	Critical	
Uptake of diagnostic test for Obstructive Sleep Apnea Syndrome (OSAS)											
OSAS brochure with brief education and referral for OSAS diagnostic testing vs. No intervention											
1 <sup>4</sup>	Cohort study	Serious <sup>i</sup>	Not applicable	Serious <sup>j</sup>	No serious	No	782	OR 2.24 (95%CI 1.25 to 4.01) favouring intervention	Very low	Critical	
CI Confidence intervals											
<p>1. Evans et al. 1997</p> <p>2. Sriram et al. 2016</p> <p>3. Michie et al. 2014</p> <p>4. Perraudin et al 2015</p> <p><sup>a</sup> Downgraded 2 levels. Baseline characteristics of the groups were not compared. Outcomes were self-reported. 54% of participants were successfully followed up but it is not clear how many eligible community pharmacy users were recruited into the study. The consistency of the intervention across different sites or different days was not measured.</p> <p><sup>b</sup> Downgraded by 1 level as people were only recruited to study if they approached pharmacist about minor ailment or OTC medication.</p> <p><sup>c</sup> Downgraded 1 level as number of events is less than 300.</p> <p><sup>d</sup> Downgraded by 2 levels. Very likely to be different participants in before and after group. No comparison of characteristics in before and after groups, except gender. Outcome assessors likely to be aware of intervention status of participants. Self-reported uptake of referral.</p> <p><sup>e</sup> Downgraded 2 levels as confidence intervals crosses the upper minimally important difference (1.25) and number of events is less than 300.</p> <p><sup>f</sup> Downgraded 1 level. It is unclear how the allocation sequence was generated. It is unclear how the allocation was concealed. It is unclear whether primary outcomes were assessed blindly.</p> <p><sup>g</sup> Downgraded 1 level. Outcome is use of 'effective contraception', defined as contraception that is not barrier method and not no contraception (so therefore hormonal or LARC). There will be other people who took up the service who decided not to use 'effective' contraception.</p> <p><sup>h</sup> Only includes data from participants with follow up data. Overall quality not downgraded.</p> <p><sup>i</sup> Downgrade 1 level. Selection bias into study likely to have occurred</p> <p><sup>j</sup> Downgrade 1 level. Uncertainty how applicable results are to UK setting and population</p>											

## Appendix G – Economic evidence study selection

No relevant economic studies were identified.

## Appendix H – Economic evidence tables

No studies were identified for inclusion in the economic review.

## Appendix I – Health economic evidence profiles

N/A

## Appendix J – Health economic analysis

N/A

## Appendix K – Excluded studies

[See separate appendix K document.](#)

## Appendix L – Research recommendations

*Is referral from a community pharmacy within a formal local care pathway framework more effective and cost effective than signposting alone in improving access to, and uptake of services by high risk groups and the general population?*

### Rationale

Community pharmacies have to be integrated within the care pathway, with inward and outward referrals established and consistently managed. This is in line with the NHS sustainability and transformation partnerships (STPs) and the Five Year Forward View, to have a better integration of health care services in the UK. But there is no evidence to show whether it is effective and cost effective for them to offer a broad or narrow set of services. It is also not clear how to effectively refer in and out of pharmacies to improve patient outcomes.

Some evidence showed that referral by community pharmacies increased service uptake more than signposting but more research is needed to support this. Establishing cost-effectiveness evidence for this in pharmacies is important because the resource impact for making and receiving referrals is greater than for signposting. For example, there may be cost implications for the time needed to make or accept individual referrals and for setting up the overall process.

Criterion	Explanation
Population	General population (primary prevention) and high risk groups (secondary prevention)



Intervention	Referral within a formal local care network
Comparators	Signposting alone
Outcomes	Access to services elsewhere in the network  Uptake of services or interventions elsewhere within the network  Costs, savings and effectiveness
Study design	Study designs could include cost-effectiveness studies and RCTs of specific referral interventions or other types of evaluation with the purpose of ascertaining the effect of formal referrals in improving service uptake. It will also be important to gain public and staff feedback as part of any studies so a mixed methods approach to include qualitative elements may also be appropriate.
Timeframe	No specific timeframe

*How effective and cost effective is it for community pharmacy teams to provide local social prescribing interventions? What is the differential impact in both effectiveness and cost effectiveness of community pharmacies carrying out this activity or acting only as a referral or signposting element of the approach?*

### **Rationale**

The committee noted that social prescribing is an important concept to consider when signposting and referring people from community pharmacies. Social prescribing schemes can involve various activities to support people's social, emotional or practical needs. Examples include volunteering, arts activities, group learning, debt counselling, gardening, befriending, cookery and sports.

The main goal of social prescribing is to promote better patient outcomes. It may also help to reduce referrals to the acute sector or uptake of more costly interventions. But currently there is no evidence on its effectiveness – or acceptability – in community pharmacies.


Criterion	Explanation
Population	General population (primary prevention) and high risk groups (secondary prevention)
Intervention	Social prescribing. This could include UK-specific social prescribing referrals and

	interventions which are already being provided in community pharmacies, but do not currently have an evidence base.
Comparators	<p>Social prescribing by others in the local care network</p> <p>Other non-social prescribing interventions</p> <p>Signposting verses referral for social prescribing</p> <p>No intervention</p>
Outcomes	<p>Uptake of social prescribing interventions</p> <p>Clinical measurements or health outcomes</p> <p>Behavioural outcomes (action)</p> <p>Modifying factors or determinants of behaviour (awareness, knowledge, attitudes, intentions)</p> <p>Wellbeing, Quality of Life</p> <p>Costs, savings and effectiveness</p>
Study design	<p>Study designs could include cost-effectiveness studies and RCTs of specific interventions or other types of evaluation with the purpose of ascertaining what interventions are effective at providing social prescribing, specifically within a UK context. It will also be important to gain public and staff feedback as part of any studies so a mixed methods approach to include qualitative elements may also be appropriate.</p>
Timeframe	<p>Studies would require sufficient follow up time to capture impacts on health and wellbeing</p>

## Appendix M – Expert testimony

[See separate appendix M document](#)

## Appendix N – PRISMA diagram



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The PRISMA Statement. *PLoS Med* 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit [www.prisma-statement.org](http://www.prisma-statement.org).